WHO Drug Information Vol 22, No

Home , Foravirumab, Rafivirumab, Strontium ranelate

WHO DRUG

INFORMATION

VOLUME 22 NUMBER 2 2008

PROPOSED INN LIST 99 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES

WORLD HEALTH ORGANIZATION GENEVA WHO Drug Information Vol 22, No. 2, 2008 World Health Organization

WHO Drug Information

Contents Access to Medicines Lapatinib and hepatoxicity 96 Telbivudine and peripheral neuropathy 96 WHO prequalification: progress in 2007 79 International Nonproprietary Safety and Efficacy Issues Names Update on safety of heparin 84 International Nonproprietary Names Nicorandil-associated ulceration 85 for monoclonal antibodies: IFPMA Topiramate and other drugs causing proposal 97 glaucoma 86 Varenicline: serious psychiatric reactions 86 Montelukast : safety review 88 Regulatory Action and News Neurocognitive effects of chemotherapy 89 Dydrogesterone withdrawn for New MMRV vaccine recommendations 89 commercial reasons 108 Oseltamivir label updated with neuro- Enoxaparin contamination: batches psychiatric warning 90 recalled 109 Ketoconazole tablets: risk of hepato- Recombinant antihemophilic factor toxicity 90 approved 110 Alemtuzumab: infection-related deaths 91 Rotavirus vaccine approved 111 Mycophenolate mofetil: progressive New version of genetically engineered multifocal leukoencephalopathy 91 Factor VIIa approved 111 Modafinil: serious rash and psychiatric symptoms 92 Moxifloxacin: serious hepatic and skin International Pharmacopoeia reactions 92 Role of The International Pharmacopoeia Rimonabant: depression; psychiatric in quality assurance 113 reactions 93 Exenatide: risk of acute pancreatitis 94 Zanamivir: neuropsychiatric events 94 Proposed International Inosine ponophosphate dehydrogenase Nonproprietary Names: inhibitors: congenital anomalies 94 Strontium ranelate : life-threatening List 99 121 allergic reactions 95

77 WHO Drug Information Vol 22, No. 2, 2008

WHO Drug Information is also available online at http://www.who.int/druginformation

NEW ! WHO Drug Information DIGITAL LIBRARY with search facility at http:// www.who.int/druginformation

Subscribe to our e-mail service and receive the table of contents (PDF) of the latest WHO Drug Information

To subscribe: send a message to

[email protected] containing the text:

subscribe druginformation

78 WHO Drug Information Vol 22, No. 2, 2008

Access to Medicines

WHO prequalification: products. This offers a considerable increase in the choice of prequalified progress in 2007 medicines for these diseases. The Prequalification Programme for The total number of prequalified products medicinal products is a service provided in 2007 was the lowest since 2001. The by the World Health Organization (WHO) main reasons for this are: to facilitate access to medicines that meet international unified standards of quality, • decreasing number of new submissions; safety and efficacy for HIV/AIDS, malaria, tuberculosis and reproductive health. • submitted dossiers did not include sufficient evidence to prove quality, Work is carried out through: safety and efficacy of products; and • stringent assessment of pharmaceutical • little additional substantive evidence product dossiers; was provided in support of dossiers previously submitted. • inspection of pharmaceutical manufacturing sites (both for finished dosage Certain product groups are urgently in forms and active pharmaceutical ingre- need of expansion to increase available dients) and contract research organiza- treatment options, i.e., second-line anti- tions (CROs); tuberculosis and paediatric antiretroviral combination products. In 2007, only one • prequalification of pharmaceutical antituberculosis treatment submission quality control laboratories (QCLs); and and two new submissions for paediatric • advocacy for medicines of assured antiretrovirals were presented for WHO quality. Prequalification.

The Programme also provides high-level In the past year, the number and quality training, capacity building and technical of product dossiers submitted for assess- assistance to stakeholders from both the ment was very uneven. Conversely, a private and public sectors. The Bill & considerable number of new applicants Melinda Gates Foundation as well as approached WHO. However, most of the UNITAID are currently the principle newcomers have limited or no experience financial supporters of the WHO Prequali- in production to international standards fication Programme. and are not yet capable of generating the required evidence. The manufacturing New prequalified products conditions and quality specifications presented for reproductive health and Twenty-one products were added to the list antimalarial products were particularly of prequalified medicines in 2007 – all but poor. one being generics. The number of prequalified medicines now stands at 156. Efforts needed to reach A major achievement in 2007 was the prequalification status prequalification of five new products to The products prequalified in 2007 were, treat tuberculosis and three antimalaria on average, under assessment and

79 Access to Medicines WHO Drug Information Vol 22, No. 2, 2008

Summary of activities in 2007

The WHO Prequalification Programme:

• Prequalified a total of 21 medicinal products, including 5 anti-tuberculosis and 3 anti-malarial medicines • Intensified and widened the scope of prequalification of quality control laboratories • Doubled the number of training workshops for capacity building in resource- limited countries • Organized 10 technical assistance missions for manufacturers to support improvements in the quality of their products • Planned and implemented a comprehensive sampling and testing programme • Developed guidelines and standards to facilitate global quality assurance activities, including pharmacopoeial monographs and chemical reference substances • Undertook special efforts to facilitate development of paediatric formulations • Recruited additional full-time staff to maintain sustainability and improve perform- ances of prequalification process • Streamlined the process between receiving a complete dossier and the first assessment or inspection of manufacturing sites • Developed tools to increase transparency and allow monitoring of the prequalification process adjustment for two years before attaining Maintaining the list compliance with international standards. of prequalified medicines During this period, eight to nine assess- Inclusion in the list does not mean that ment sessions and five inspections were the prequalified status of a product lasts required before the ultimate positive forever. All prequalified medicines have conclusions were reached. Thus, consid- to be checked regularly in order to ensure erable time and resources are needed that any changes undertaken by manu- from applicants, as well as dedication to facturers do not undermine the quality, implementing the necessary corrective safety and efficacy of the products. action, to meet international quality standards. In order to reach this objective, WHO assesses variations in manufacture and All involved stakeholders agree and carries out random quality control tests of understand that expansion of the list of prequalified medicines, as well as re- prequalified medicines can only be inspections of manufacturing sites. As the realized if capacity building and technical prequalified products list is constantly assistance activities increase in resource- growing, maintaining and updating the limited countries. Therefore, such actions information becomes increasingly impor- have become one of the core objectives tant in order to ensure the quality and of the Prequalification Programme. safety of the medicines.

80 WHO Drug Information Vol 22, No. 2, 2008 Access to Medicines

Training Workshops organized in 2007

Date Location Content of training

16–20 April Cape Town, Pharmaceutical development with a South Africa focus on paediatric medicines

6–7 June Cairo, Egypt WHO Prequalification Programme – introduction for EMRO countries

25–27 June Kiev, Ukraine Dissolution, pharmaceutical product inter-changeability and biopharma- ceuticals classification system

10–14 September Dar Es Sallam, Assessment of dossiers based on Tanzania WHO Prequalification guidelines for staff of East Africa Community national medicine regulatory authorities

15–19 October Tallinn, Estonia Pharmaceutical development with a focus on paediatric medicines

5–9 November Jiaxing, China Pharmaceutical quality, Good Manufac turing Practice and bioequivalence with a focus on anti-tuberculosis products

26–29 November Rabat, Morocco Quality assurance, Prequalification and quality control in quality control laboratories

10–14 December Dakar, Senegal Good Manufacturing Practice training course for countries of francophone Africa

5–7 December Dar Es Sallam, Quality assurance, Prequalification and Tanzania development of standards in quality control laboratories

Capacty building groups, including staff from regulatory for regulatory authorities agencies and quality control laboratories, Recognizing the importance of capacity and for manufacturers. Such training building through training and hands-on includes group sessions as well as practice, the WHO Prequalification communication between involved parties, programme organized nine training such as manufacturers and the present- courses in 2007 and co-organized four ers, who are themselves part of the training activities together with other assessment or inspection teams working partners in nine different countries. with the Prequalification Programme. These exercises offered tuition on gen- In 2007, four national regulatory experts eral or specific technical issues for larger from Ethiopia, Tanzania, Uganda and

81 Access to Medicines WHO Drug Information Vol 22, No. 2, 2008

Zimbabwe were offered a full-time posi- Dossier assessments tion at WHO for three months. The and expert advice objective was to create a rotational In 2007, six assessment sessions were network between WHO and resource- organized at the UNICEF Supply Division limited countries, increase capacity in Copenhagen where the product dossi- building of national regulatory authorities ers are received and stored. In total, 39 and enhance information exchange external assessors from both well and between all parties. less resourced regulatory authorities participated in the assessment sessions. Technical assistance It is worth noting that regulators from the to manufacturers WHO Africa Region have been especially Since 2006, the WHO Prequalification active in the process. programme has provided coordinated technical assistance aimed at resolving In addition to regular assessment acti- specific practical problems encountered vities, considerable increase in expert by manufacturers or quality control scientific advice provided to applicants laboratories. Assistance is given by a was observed in 2007 – a total of 16 qualified professional in the form of an bioequivalence study protocols were audit and training in technical or regula- reviewed, with more than 80 bioequiva- tory areas. lence queries answered, and 35 separate quality issues handled by the respective In 2007 alone, the WHO Prequalification expert panels. programme provided a total number of 13 technical assistance sessions in nine Inspections different countries, compared to six in A total of 45 inspections were carried out four countries in 2006. in seven different countries in 2007, with 35 taking place in India. As in the previ- To avoid conflict of interest, WHO uses a ous year, considerable assistance with pool of specialists working either for inspections was received from national nonprofit organizations or acting as inspectorates belonging to The Pharma- individual technical consultants unrelated ceutical Inspections Convention and to prequalification activities. These Pharmaceutical Inspection Cooperation experts are not involved in assessments Scheme (jointly referred to as PIC/S). As and inspections. in 2006, France, was the leading country in terms of providing inspection support.

Technical assistance organized by WHO Prequalification Programme in 2007

Date Location Content of technical assistance 6–9 February Ukraine Stability studies and GMP 5–10 March China GMP of manufacture under aseptic conditions 26 March – 2 April Cambodia GMP of packaging combination products 1–5 May Zimbabwe GMP of antiretroviral products 20–26 May India Manufacturing process validation and GMP 17–29 July Cambodia GMP of packaging combination products 23–29 August Bangladesh Pharmaceutical engineering and GMP 04–09 November Zimbabwe GMP of antiretroviral products 17–21 December India Manufacturing process validation and GMP 17–22 December China GMP of manufacture under aseptic conditions

82 WHO Drug Information Vol 22, No. 2, 2008 Access to Medicines

Prequalification assessment and inspection statistics: 2007 Dossier Assessment Assessment sessions in Copenhagen 6 Total number of assessment days 42 Total number of assessment reports 463 Assessment reports on HIV/AIDS products 298 Assessment reports on TB products 100 Assessment reports on malaria products 54 Assessment reports on reproductive health products 11

Inspections Manufacturing sites of finished product manufacturers 26 Manufacturing sites of active pharmaceutical ingredients 6 Contract research organizations 13 National pharmaceutical quality control laboratories 1

Prequalification of quality Developments to the website at http:// control laboratories www.who.int/prequal include: One laboratory was prequalified in 2007, while 12 laboratories expressed interest • creation of a public tool to monitor in prequalification but only seven submit- dossier status of products currently ted the required information file. The under evaluation; Programme carried out six pre-audit visits • more and better guidance for applicants; and inspectors concluded that all applicants needed training and technical • new invitations to manufacturers of HIV, assistance. antimalaria, antituberculosis and reproductive health products; Strengthening and transparency of activities • publication of the annual report in six In January 2007, there were five full-time languages; professional staff members working for • creation of a section in Chinese to the WHO Prequalification Programme — accommodate the translated documents a number that increased to 12 by the end on prequalification; and of the year. A database to log and track dossier assessment and inspections was • creation of a searchable and custom- developed and became operational in ized registry of prequalified medicines. 2007.

83 WHO Drug Information Vol 22, No. 2, 2008

Safety and Efficacy Issues

Update on safety of heparin tests are now mandatory for batch release of all heparin API preparations in World Health Organization — On 17 the USA (3). January 2008, Baxter Healthcare Corpo- ration began voluntary recall of nine lots In Germany, 80 or more recent cases of of heparin sodium in the USA. The ad- similar adverse events (no deaths) verse events are described as acute relating to specific batches of heparin allergic-type reactions and have been products manufactured by Rotexmedica documented by the US Centers for GmbH have also been reported. Disease Control (CDC) (1). The number Rotexmedia initiated a recall on several of recent adverse reactions associated batches of heparin injection in early with the Baxter heparin preparations is March 2008 (4). The origin of the heparin over 700, including 19 deaths. The US in these products is the Changzhou Food and Drug Administration (FDA) and Quianhong Bio Pharma Co. Ltd., China, Baxter are conducting an investigation and the Yantai Dongcheng Biochemicals into these clusters of adverse reaction Co., China. reports. Further recalls of heparin products from The active pharmaceutical ingredient other suppliers have followed more (API) for the batches of heparin associ- recently, in the USA and elsewhere. ated with adverse reactions originated Heparin is on the WHO Model List of from the Scientific Protein Laboratories Essential Medicines, and WHO distrib- (SPL) Changzhou facility in China. The utes the 5th International Standard FDA investigation included inspections of Heparin for measurement of the potency the manufacturing plants in China and the of unfractionated heparin preparations USA. The FDA’s report of its inspection of according to methods outlined in the the Changzhou SPL manufacturing plant International Pharmacopoeia. Other was critical of several aspects of its WHO International Standards for heparin processes. are the low molecular weight heparin standards for both biological activity and The US FDA has found that heparin for molecular weight calibration. All the batches associated with adverse reac- WHO International Standards for heparin tions contain 5–20% by weight of a have been found to be free of contamina- “heparin-like compound which is not tion according to criteria defined in the heparin” contaminant. The contaminant most recent version of the FDA’s “Impu- has been identified as an oversulfated rity evaluation of Heparin Sodium by chondroitin sulfate (2). The FDA has NMR Spectroscopy” (5). published two screening methods which can identify the presence of the heparin- Adverse reactions to heparin products like contaminant oversulfated chondroitin should be reported to the appropriate sulfate; one of them involves proton National Regulatory Authority. WHO has nuclear magnetic resonance (NMR) a programme on International Drug spectroscopy, and the other involves Monitoring, co-ordinated by the Uppsala capillary electrophoresis (CE). These Monitoring Centre, Uppsala, Sweden (6).

84 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

WHO can offer advice and help to na- Subsequently, ulceration has been tional regulatory authorities in countries reported at other sites, including anal, with limited resources for the characteri- perianal, vulvar, perivulvar, gastrointesti- zation of suspect batches of heparin API, nal and parastomal tissues, and various including testing by NMR and CE as cutaneous sites, including the lower recommended by the FDA, through the anterior leg, natal cleft, umbilicus and WHO Collaborating Centre for Biological areas affected by flexural psoriasis; Standards. ulcers may occur at multiple sites (2, 3). The reaction occurs rarely, appears to be The WHO Expert Committee on Specifi- dose-related and the time to ulcer onset cations for Pharmaceutical Preparations, may be up to months after starting which oversees the activities related to nicorandil. The ulcers are persistent, The International Pharmacopoeia, to- deep and ‘punched out’ in appearance, gether with the WHO Expert Committee with non-specific inflammatory histology. on Biological Standardization, will review Their pathogenesis remains unclear. the above information as well as appropriate validated tests for impurity evaluation Unless nicorandil is recognized as a of unfractionated heparin. potential cause and the drug withdrawn, the ulcers are likely to persist despite References other treatment. Conservative ulcer management is ineffective and surgery 1. http://www.cdc.gov/mmwr/pdf/wk/mm57 may exacerbate the tissue damage. e201.pdf Typically any discomfort resolves quickly 2. http://www.fda.gov/bbs/transcripts/2008/ after nicorandil is withdrawn, although heparin_transcript_ 031908.pdf healing may take considerably longer.

3. http://www.fda.gov/cder/drug/infopage/ Seven of 51 reports received by the heparin/default.htm Therapeutic Goods Administration (TGA) 4. http://www.rotexmedica. com/index.php? for nicorandil describe ulceration. Six of page_id=18 the seven reports described tongue or mouth ulcers. Failure to recognize 5. http://www.fda.gov/cder/drug/infopage/ nicorandil-induced ulceration can lead to heparin/Heparin_NM_method.pdf substantial morbidity, inappropriate 6. http://www.who-umc.org/DynPage.aspx investigation and treatment, and unnec- essary surgery. 7. World Health Organization. http:// www.who.int/medicines and http://www.who. Extracted from Australian Adverse Drug int/biologicals Reactions Bulletin, Volume 27, Number 2, April 2008 Nicorandil-associated ulceration References Australia — Nicorandil (Ikorel®) is a 1. Reichert S et al. Major aphthous stomatitis synthetic nicotine derivative, which induced by nicorandil. Eur J Dermatol 1997; 7: causes arterial and venous dilatation. 132–3. It is indicated for the treatment of chronic 2. Watson A et al. Nicorandil induced anal stable angina pectoris at a dose of ulceration. Lancet 2002; 360: 546–7. 10–20 mg daily. Nicorandil-associated ulceration was 3. McKenna DJ et al. Nicorandil-induced leg ulceration. Br J Dermatol 2007; 156: 394–6. initially reported in oral mucosa (1).

85 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008

Topiramate and other drugs proposed for this reaction, but because causing glaucoma pupillary block is not involved, pilocarpine and iridotomy are generally ineffective. Australia —Topiramate is an antiepileptic Permanent vision loss can occur if the indicated for either monotherapy or add- condition is not managed appropriately on therapy in adults and in children aged (3). Of note is that migraine itself may two years and over; and for the prophy- cause eye pain and it is important that laxis of migraine in adults. It has an non-migraine causes should be consid- authority required Pharmaceutical Ben- ered in patients treated with topiramate efits Schedule (PBS) listing for the for migraine, who present with eye pain. treatment of epilepsy, and was recently PBS-listed as a third-line agent for the Extracted from Australian Adverse Drug prophylaxis of migraine. Reactions Bulletin, Volume 27, Number 2, April 2008 Topiramate has been rarely associated with the development of angle-closure References glaucoma. To date, the Therapeutic 1. Lin J, Fosnot J and Edmond J. Bilateral Goods Administration (TGA) has received angle closure glaucoma in a child receiving 11 reports of glaucoma associated with oral topiramate. Journal of American Associa- the use of topiramate out of 175 total tion for Pediatric Ophthalmology and Strabis- reports for the drug, Five patients had mus [JAAPOS] 2003; 7: 66-68. recovered at the time of reporting, three had not yet recovered, and recovery 2. Fraunfelder FW et al. Topiramate-associ- status was unknown in the other three. ated acute, bilateral, secondary acute-angle closure glaucoma. Ophthalmology 2004 Although all of these cases have involved Jan;111(1):109-11. adults, a literature report has described 3. Levy et al. Topiramate-induced bilateral bilateral angle-closure glaucoma present- angle-closure glaucoma. Can J Ophthalmol ing as headache, nausea, and fatigue in 2006; 41: 221-225. a five year old girl 10 days after starting topiramate (1). Varenicline: serious A published review of reports of ocular psychiatric reactions reactions to topiramate included 86 cases of acute glaucoma, 83 of which were Canada — Varenicline tartrate bilateral (2). In this series, time to onset (Champix®) has been marketed in was one to 49 days after starting Canada since April 2007 and is indicated topiramate, with 85% of cases occurring for smoking-cessation treatment in adults in the first two weeks of treatment. in conjunction with smoking-cessation Permanent vision loss was described in counselling (1). The efficacy of seven reports. Topiramate was also varenicline in smoking cessation is associated with a number of other ocular believed to be a result of the drug’s partial adverse effects, including acute myopia, agonist activity at the nicotinic acetylcho- suprachoroidal effusions, periorbital line receptor. By binding to these oedema, and scleritis (2). receptors, varenicline induces 2 results (2). First, it signals the release of Management of topiramate-induced dopamine and creates similar reinforcing glaucoma involves immediate cessation effects, but not to the full extent that of topiramate and urgent medical treat- nicotine does because of its partial ment of the glaucoma as required. A binding of the receptor (2). Second, it acts number of mechanisms have been as a physical antagonist by binding to the

86 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

Table 1: Summary of reports of aggression, depression and suicidal tendency suspected of being associated with varenicline submitted to Health Canada from 1 April 2007 to 23 Noveber 2007*

Case/Patient History of Adverse reaction(s)† Time to Outcome after age/sex psychiatric onset of discontinuation condition reaction, of varenicline d‡

1. 51/F No Aggressiveness 4 Unknown

2. 65/M Yes Aggressiveness 36 Recovered

3. 46/M Yes Depression 1 Recovered

4. 55/F Unknown Depression <2 Recovered

5. 64/M No Depression 2 Recovered

6. NA/F Yes Depression <42 NA§

7. 64/F Unknown Depression Unknown NA¶

8. 33/F No Suicidal tendency 11 Unknown

9. 55/F Unknown Suicidal tendency <14 Unknown

10. 53/F No** Suicidal tendency/ <29 Recovered depression

11. 30/F Unknown Suicidal tendency/ <31 Unknown depression

12. 46/M No Suicidal tendency/ <32 Recovered depression

13. 54/M No Suicidal tendency/ <72 Recovered depression

14. 58/F Yes Suicidal tendency/ <13 Recovered depression/anger

Note: NA = not available.

* These data cannot be used to determine the incidence of adverse reactions (ARs) because ARs are underreported and neither patient exposure nor the amount of time the drug was on the market has been taken into consideration. † Terms are listed according to the World Health Organization Adverse Reaction Terminol- ogy (WHOART). ‡ Estimated from the beginning of treatment. § At the time of reporting, the patient was still taking varenicline and had not yet recovered. ¶ The onset of depression was after the discontinuation of the drug. ** Family history of depression was reported.

87 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008

nicotine receptor and by blocking the 2. Stack NM. Smoking cessation: an overview effects of nicotine or a nicotine-replace- of treatment options with a focus on vareni- ment agent (2). cline. Pharmacotherapy 2007;27(11): 1550–7. Smoking cessation with or without treat- 3. Freedman R. Exacerbation of schizophrenia ment is associated with various symp- by varenicline. Am J Psychiatry 2007;164(8): toms such as depressed mood, insomnia, 1269. irritability, frustration or anger, and anxiety (1). From 1 April to 23 November 2007, 4. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar Health Canada received 107 reports of disorders. Am J Psychiatry 2007; 164(8): adverse reactions (ARs) suspected of 1269–70. being associated with varenicline. Of these reports, 46 described psychiatric ARs of which 14 reported cases of Montelukast : safety review aggression, depression or suicidal idea- United States of America — The Food tion (table 1). The remaining cases of and Drug Administration (FDA) is investi- psychiatric disorders included ARs such gating a possible association between the as amnesia, abnormal dreams, anxiety, use of montelukast (Singulair®) and insomnia, abnormal thinking and somno- behavior/mood changes, suicidality and lence. suicide. Montelukast is a leukotriene receptor antagonist used to treat asthma The impact of a smoking-cessation pro- and symptoms of allergic rhinitis, and to duct with partial nicotinic-receptor agonist prevent exercise-induced asthma. properties in patients with underlying psychiatric illness is unknown, and care Over the past year, the manufacturer has should be taken with these patients (1). updated the prescribing and patient Two case reports recently described the information to include the following post- exacerbation of schizophrenia in one marketing adverse events: tremor (March patient (3) and a manic episode in a 2007), depression (April 2007), suicidality patient with bipolar disorder taking vare- (October 2007), and anxiousness (Febru- nicline (4). ary 2008).

The Canadian Product Monograph for FDA is working with the manufacturer to varenicline was recently revised to further evaluate a possible link between indicate that there have been postmarket the use of Singulair® and behavior/mood reports of depressed mood, agitation, changes, suicidality and suicide. Until changes in behaviour, suicidal ideation further information is available, healthcare and suicide (1). The product monograph professionals and caregivers should states that not all patients had known pre- monitor patients for suicidality or changes existing psychiatric illness and not all had in behavior and mood. completely discontinued smoking (1). Other leukotriene modifying medications Extracted from Canadian Adverse Reac- include zafirlukast (Accolate®), which is tion Newsletter, Volume 18, Issue 2, April also a leukotriene receptor antagonist 2008 and zileuton (Zyflo® and Zyflo CR®), which is a leukotriene synthesis inhibitor. References FDA is reviewing postmarketing reports it has received of behavior/mood changes, 1. Champix (varenicline tartrate tablets) [product monograph]. Kirkland (QC): Pfizer suicidality and suicide and will assess Canada Inc; 2007. whether further investigation is warranted.

88 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

Reference: Information from FDA dated 27 the risk for febrile seizures among chil- March 2008 at http://www.fda.gov/medwatch dren aged 12—23 months after administration of the combination measles, Neurocognitive effects of mumps, rubella, and varicella (MMRV) chemotherapy vaccine (ProQuad®). ACIP updated recommendations remove ACIP’s previ- Australia —There is growing evidence ous preference for administering combi- that some patients who survive cancer nation MMRV vaccine over separate can suffer neurocognitive impairment injections of equivalent component after chemotherapy. vaccines (i.e., measles, mumps, and rubella [MMR] vaccine and varicella Although the symptoms are generally vaccine). subtle and improve after ceasing chemotherapy, for some survivors the symptoms The combination tetravalent MMRV are sustained and can impact significantly vaccine was licensed by the Food and on their quality of life. Some studies have Drug Administration (FDA) on 6 Septem- reported that 15–50% of patients have ber 2005, for use in children aged 12 cognitive impairment after chemotherapy months–12 years (1). MMRV vaccine can for solid tumours. Areas most affected are be used in place of trivalent MMR vaccine usually attention, concentration, verbal and monovalent varicella vaccine to and visual memory and processing implement the recommended 2-dose speed. vaccine policies for prevention of measles, mumps, rubella, and varicella (1, 2). Studies published in the past few years The first vaccine dose is recommended at report that up to 30% of patients with age 12–15 months and the second at age solid tumours may have cognitive impair- 4–6 years. ment before receiving chemotherapy. It is likely that the regimen, dose and In MMRV vaccine prelicensure studies, duration of chemotherapy influence the an increased rate of fever was observed incidence and severity of cognitive 5–12 and 0–42 days after the first vaccine impairment. Studies have found higher dose, compared with administration of rates of cognitive dysfunction in patients MMR vaccine and varicella vaccine at the receiving high doses of chemotherapy same visit (3, 4). Because of the known compared to those on standard doses. association between fever and febrile There are no proven interventions to seizures (5), CDC and Merck initiated prevent impairment and the mainstay of postlicensure studies to better understand therapy is to treat any depression and the risk for febrile seizures that might be anxiety. associated with MMRV vaccination.

Reference: Australian Prescriber Media ACIP also recommended establishing a Release, 4 February 2008 at http:// www.tga.gov.au work group to conduct in-depth evaluation of the findings regarding the increased risk for febrile seizures after the first dose New MMRV vaccine of MMRV vaccine to present for consid- recommendations eration of future policy options. CDC, United States of America — On 27 FDA, and ACIP will communicate updates February 2008, new information was and implement further necessary actions presented to the Advisory Committee on based on these evaluations (6). Immunization Practices (ACIP) regarding

89 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008

References Reference: Physician’s First Watch, 5 March 2008. 1. CDC. Licensure of a combined live attenu- ated measles, mumps, rubella, and varicella Ketoconazole tablets: vaccine. MMWR 2005;54:1212—3. risk of hepatotoxicity 2. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immuniza- United Kingdom — Following a system- tion Practices (ACIP). MMWR 2007;56(No. atic review of all available data, the RR-4). manufacturer of ketoconazole (Nizoral ®) tablets has released information on a 3. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, change to the Summary of Product rubella and varicella vaccine in healthy Characteristics (SmPC) because of a risk children. Pediatr Infect Dis J 2005;24:665—9. of serious hepatotoxicity and the availabil- ity of other effective antifungal treatments. 4. Merck & Co., Inc. ProQuad® (measles, Nizoral® tablets are now indicated for: mumps, rubella, and varicella [Oka/Merck] virus vaccine live) [package insert]. • Treatment of dermatophytosis and Whitehouse Station, NJ: Merck & Co., Inc.; 2005. Malassezia (previously called Pityrosporum) folliculitis that cannot be 5. Seizures in childhood. In: Kliegman RM, treated topically because of the site, Behrman RE, Jenson HB, Stanton BF, eds. extent of the lesion or deep infection of Nelson textbook of pediatrics. 18th ed. the skin, in patients resistant to, or Philadelphia, PA: Saunders; 2007:2457—75. intolerant of, fluconazole, terbinafine 6. Update: Recommendations from the and itraconazole. Advisory Committee on Immunization Prac- tices (ACIP) Regarding Administration of • Treatment of chronic mucocutaneous Combination MMRV Vaccine. MMWR Morbid- candidiasis, cutaneous candidiasis, and ity & Mortality Weekly Report. March 14, oropharyngeal candidiasis that cannot 2008. 57(10);258-260 be treated topically because of the site, extent of the lesion or deep infection of Oseltamivir label updated with the skin, in patients resistant to or neuropsychiatric warning intolerant of both fluconazole and itraconazole. United States of America —The product label for oseltamivir phosphate (Tamiflu®) In addition to the existing drug interac- has been revised to include a warning tions and contraindications, several other about possible neuropsychiatric events. drugs have been added to the list of The updated label is based on recom- contraindicated drugs, including: diso- mendations from the agency’s Pediatric pyramide; sertindole; nisoldipine; eplere- Advisory Committee meeting in Novem- none; and ergot alkaloids such as di- ber 2007. hydroergotamine, ergometrine (ergono- vine), ergotamine and methylergometrine Postmarketing reports indicate that some (methylergonovine) patients with influenza who were receiving oseltamivir had delirium and abnormal Very rare cases of serious hepatic toxic- behavior, leading to injury and even ity, including cases with a fatal outcome death. Most of the cases occurred in or requiring liver transplantation, have children and in Japan. The label now occurred with the use of oral ketocona- cautions clinicians to monitor their pa- zole. Some patients had no obvious risk tients for abnormal behavior when taking factors for liver disease. the drug.

90 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

The risk of serious hepatic toxicity in- in this trial are the result of a prolonged creases with longer duration of treatment; period of immunosuppression resulting courses of greater than 10 days should from the sequencing of these drugs only be given after full consideration of without sufficient time for recovery, as the extent of treatment response and the well as other factors specific to this trial. risk benefit of continuing treatment. Liver function must be monitored in all patients The five fatal infections were reported as: receiving treatment with Nizoral® tablets. viral meningitis, Listeria meningitis, Legionella pneumonia, cytomegalovirus The following Postmarketing adverse infection and Pneumocystis jiroveci drug reactions have been added: anaphy- pneumonia, all in patients who achieved lactoid and anaphylactic reactions; a complete response after induction angioneurotic oedema; adrenocortical therapy. insufficiency; cirrhosis, the reporting rate being very rare. References: Reference: Communication from Janssen- 1. Communication from Bayer Schering Cilag Ltd January 2008 \\mhralonfs01\home$\ Pharma AG and Genzyme Europe BV at http:/ tilstonec\Website\Feb 2008\Nizoral DDL.doc /www.mhra.gov.uk on the Medicines and Healthcare products Regulatory Agency (MHRA) website at http:// 2. Lin TS, Donohue KA, Lucas MS, Byrd JC, www.mhra.gov.uk/Safetyinformation Bengtson EM, Peterson BL, Larson RA (Cancer and Leukemia Group B USA). Consolidation therapy with subcutaneous (SC) Alemtuzumab: infection- alemtuzumab results in severe infections related deaths toxicity in previously untreated CLL patients who achieve a complete response (CR) after United Kingdom — Bayer Schering fludarabine and rituximab (FR) induction Pharma AG and Genzyme Europe BV therapy: Interim Satefy Analysis of the CALGB have informed physicians of six infection- Study 10101. Blood 2007 Nov;110(11): 232a– related deaths, reported from a trial 233a, [Abstract 755] (CALGB10101) in which previously untreated, symptomatic B-cell chronic 3. CALGB10101 abstract available online at lymphocytic leukemia (CLL) patients were http://www.hematology.org. treated with fludarabine and rituximab followed by alemtuzumab for remission Mycophenolate mofetil: consolidation. progressive multifocal leukoencephalopathy Alemtuzumab (MabCampath®) is approved for the treatment of patients with European Union — In agreement with B-cell chronic lymphocytic leukaemia (B- the European Medicines Agency (EMEA), CLL) for whom fludarabine combination the manufacturer of mycophenolate chemotherapy is not appropriate and mofetil (CellCept®) has advised physi- should not be used as consolidation cians of new safety information. therapy following induction with CellCept® has been on the market for fludarabine + rituximab outside of a over 10 years, as an immunosuppressive clinical trial. agent indicated in combination with ciclosporin and corticosteroids. Fludarabine, rituximab and alemtuzumab all have known immunosuppressive Isolated cases of progressive multifocal properties, and it is possible that the fatal leukoencephalopathy (PML) have been infectious complications which occurred reported in patients receiving CellCept®.

91 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008

The case reports have been associated Modafinil should be discontinued at the with confounding factors in particular the first sign of rash and not restarted nature of the underlying disease, con- unless the rash is clearly not drug- comitant immunosuppression and the related. latency between the use of CellCept® and the onset of PML. However, based • Psychiatric adverse experiences (psy- on the temporal relationship observed in chosis, mania, delusion, hallucinations, some cases, the contributory role of suicidal ideation and aggression) have CellCept® cannot be excluded. been reported in patients treated with modafinil. If psychiatric symptoms Leukoencephalopathy (PML) is a rare, occur, modafinil should be discontinued progressive, demyelinating disease of the and not restarted. central nervous system (CNS) that usually leads to death or severe disability. Caution should be exercised when PML is caused by the reactivation of the administering modafinil to patients with JC virus, a polyomavirus that resides in a history of psychosis, depression or latent form in 70 – 90% of the adult mania given the possible emergence or population worldwide. JC virus usually exacerbation of psychiatric symptoms. remains latent, typically only causing PML in immunocompromised patients. The Modafinil is not approved for use in factors leading to activation of the latent children for any indication. infection are not fully understood although abnormalities in T-cells have been Modafinil is indicated for the symptomatic described as important for reactivation of relief of excessive sleepiness associated JC virus and PML. Patients usually with narcolepsy, Obstructive Sleep present with focal CNS abnormalities and Apnoea/Hypopnoea Syndrome (OSAHS) radiographic evidence of white matter or moderate to severe chronic Shift Work disease without mass effect. Sleep Disorder (SWSD) in adult patients.

Reference: Communication from Roche, Reference: Communication from Cephalon P212828, 18th February 2008 at http:// dated 14/02/2008 at http://www.mhra.gov.uk www.mhra.gov.uk product information available on the electronic medicines compendium site http://emc. Modafinil: serious rash and medicines.org.uk psychiatric symptoms Moxifloxacin: serious hepatic United Kingdom —The manufacturer of modafinil (Provigil®) has informed physi- and skin reactions cians of new warnings and safety infor- United Kingdom/European Union — In mation regarding: agreement with EU regulatory authorities, including the Medicines and Healthcare • Serious skin rash and psychiatric Products Regulatory Agency (MHRA), the symptoms. The safety concern involves manufacturer of moxifloxacin (Avelox®) serious skin rashes requiring hospitali- has released important safety informa- zation and discontinuation of treatment tion. A recent assessment of adverse in adults and children occurring within 1 reactions associated with the use of to 5 weeks after treatment initiation moxifloxacin resulted in the following [isolated cases have been reported after information and recommendations: prolonged treatment (e.g. 3 months)].

92 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

• Treatment with moxifloxacin is associ- information for moxifloxacin across the ated with a risk of developing fulminant European Union. hepatitis potentially leading to life threatening liver failure and risk of Reference: Communication from Bayer potentially life threatening bullous skin Schering Pharma, Bayer plc February 2008, at reactions like Stevens-Johnson-Syn- Medicines and Healthcare products Regula- drome (SJS) or toxic epidermal necroly- tory Agency (MHRA) http://www.mhra.gov.uk sis (TEN). Rimonabant: depression; • Due to limited clinical data, moxifloxacin psychiatric reactions is contraindicated in patients with impaired liver function (Child Pugh C) United Kingdom — Rimonabant and in patients with transaminases (Acomplia®) is contraindicated in patients increased > 5 fold the upper limit of with ongoing major depression or those normal. taking antidepressants. Prescribers are encouraged to take a detailed history • Patients should be advised to stop from patients before prescribing. How- treatment and to contact their physician ever, depressive reactions may occur in if early signs and symptoms of these patients who have no obvious risk factors, reactions occur. apart from obesity itself. Liver injuries possibly related to moxifloxacin were more frequently of choles- Up to the end of January 2008, 673 ADR tatic or mixed hepatocellular-cholestatic reports (reporting 1971 individual type than of hepatocellular type. Eight reactions) had been received with reports of fatal hepatic injuries were rimonabant in the UK, 423 of which were considered as possibly related to moxi- serious. Four reports had a fatal outcome. floxacin therapy. Cases of positive re- The most common reported ADRs, which challenge gave further evidence of a are labelled in the Summary of causal relationship. However, the majority Product Characteristics, were: of patients experiencing serious liver injuries where the outcome was reported • Psychiatric disorders (depression, improved or recovered. anxiety, nervousness, irritability, sleep disorders, parasomnias) TEN was reported in several cases where • Nervous-system disorders (memory a causal relationship was considered loss, dizziness, hypoaesthesia, paraes- possible; this included two cases with thesia) fatal outcome. Additionally, a total of 35 individual cases of SJS were reported, • Gastrointestinal disorders (nausea, including three cases where there was a diarrhoea, vomiting) fatal outcome and seven cases which were considered life-threatening. In these • General disorders (fatigue, asthenia) 10 cases of severe SJS, a progression to • Skin and subcutaneous disorders TEN was documented in three patients. (pruritus, sweating) Based on the large patient exposure, the incidence of both life threatening liver 876 psychiatric reactions were reported injuries and TEN is very low, although a (44% of all 1971 reported reactions). definite frequency cannot be calculated The most common psychiatric reactions from these reports. were depression and related disorders As a consequence of this review, the of mood and associated symptoms. 52 manufacturer has revised the product reactions involved suicidal and

93 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008 self-harming thoughts or behaviours, Zanamivir: neuropsychiatric most of which were suicidal ideations events (42 reports). United Kingdom — The manufacturer of Many patients who receive rimonabant zanamivir (Relenza®) Inhalation Powder are diabetic. There have been seven has updated the package insert as a reports of hypoglycaemia/decreased result of postmarketing reports (mostly blood glucose. This type of reaction may from Japan) of delirium and abnormal be due to inadequate monitoring of blood- behaviour leading to injury in patients with glucose control in patients who influenza who were receiving neuramini- have managed to reduce calorie intake dase inhibitors, including zanamivir . without appropriate adjustment of oral antidiabetics (and possibly insulin). Therefore, patients should be observed for signs of unusual behaviour and a Reference: Drug Safety Update. Volume 1, healthcare professional should be con- Issue 10, May 2008 tacted immediately if the patient shows any signs of unusual behaviour. Exenatide: risk of acute pancreatitis Zanamivir is indicated for treatment of uncomplicated acute illness due to United Kingdom — Exenatide (Byetta®), influenza A and B virus in adults and the first-in-class incretin mimetic, is a paediatric patients 7 years of age and glucagon-like-peptide-1 analogue that older who have been symptomatic for no stimulates insulin release from pancreatic more than 2 days. cells in a glucose dependent manner. Exenatide is indicated for treatment of Reference: Communication from GSK at type 2 diabetes mellitus in combination www.gsk.com posted at http://www.fda.gov/ with metformin, with or without medwatch sulphonylureas in patients who have not achieved adequate glycaemic control on Inosine ponophosphate maximally tolerated doses of these oral dehydrogenase inhibitors: therapies. Exenatide was first marketed in congenital anomalies the European Union in November 2006. United States of America —The Food Several reports of acute pancreatitis have and Drug Administration (FDA) is aware been received in association with of reports of infants born with serious exenatide use worldwide. Up to 30 congenital anomalies, including microtia September 2007, 89 reports of pancreati- and cleft lip and palate, following expo- tis had been received: 87 from the USA sure to mycophenolate mofetil (MMF) and two from Germany. One case had a during pregnancy. MMF, the active drug fatal outcome. A UK report of acute and substance in CellCept®, is an ester of the chronic pancreatitis was received in active metabolite mycophenolic acid November 2007. (MPA), the active drug substance in Myfortic®. In most cases, the mothers If pancreatitis is suspected, exenatide were taking MMF following an organ and other potentially suspect transplant to prevent organ rejection. medicines should be discontinued. However, some mothers taking MMF were being treated for immune-mediated Reference: Drug Safety Update. Volume 1, conditions such as systemic lupus ery- Issue 10, May 2008

94 WHO Drug Information Vol 22, No. 2, 2008 Safety and Efficacy Issues

thematosus (SLE) and erythema multi- number of reports of drug rash with forme. Treatment began before their eosinophilia and systemic symptoms pregnancies and continued into the first (DRESS) associated with the use of trimester or until the pregnancy was Protos®. DRESS is a rare but serious detected. MMF is approved in the US for and life-threatening type of allergic use in the prophylaxis of organ rejection reaction to a drug. The condition starts in patients receiving allogeneic renal, with a skin rash, accompanied by a fever, cardiac or hepatic transplants and MPA is swollen glands, eosinophilia, adenopathy approved in the US for use in the prophy- and systemic involvement which may laxis of organ rejection in patients receiv- include hepatic, renal and pulmonary ing allogeneic renal transplants. In impairment. In most cases, the symptoms patients who are transplant recipients, resolved upon discontinuation of Protos® these drugs are almost always used in and with the initiation of corticosteroid combination with other immunosuppres- therapy. However, it has been reported sant drugs. that recovery can be slow and there is a risk of symptoms returning during the MMF and MPA increase the risk of recovery period. spontaneous abortion in the first trimester and can cause congenital malformations As of November 2007, 16 cases of in the offspring of women who are treated DRESS were reported to the CHMP. In during pregnancy. The labelling for both light of these reports , the CHMP con- MMF and MPA was revised in November cluded that the use of Protos® is linked to 2007 to change the Pregnancy Category an increased risk of DRESS and recom- to “D” (positive evidence of human fetal mended that warnings on severe hyper- risk, but potential benefits may warrant sensitivity syndromes, including DRESS use of the drug in pregnant women and Stevens Johnson syndrome be despite the potential risk) and to add included in the product and patient these findings about the risk of early information pregnancy loss and congenital malformations to the boxed warning. To date, the Health Sciences Agency Reference: FDA Alert, 16 May 2008 at (HSA) has not received any ADR reports http://www.fda.gov/medwatch associated with Protos® and DRESS. There is one case of a patient who developed Stevens Johnson syndrome Strontium ranelate : life- after taking both Protos® and Arcoxia® threatening allergic reactions (etoricoxib) simultaneously for about one Singapore — Strontium ranelate month. (Protos®, Servier) has been registered since July 2006 for the treatment of post- In view of this emerging safety concern, menopausal osteoporosis to reduce the prescribers are reminded to alert their risk of vertebral and hip fractures. Since patients of the risk of severe allergic its launch in Europe in 2004, Protos® has reactions and to inform them to stop been registered in 64 countries and has a Protos® immediately should a rash occur total of about 570 000 patient-years of and to seek medical advice. For patients exposure. who have stopped treatment due to hypersensitivity reactions, Protos® In November 2007, the European Medi- should not be re-introduced. cines Agency’s (EMEA) Committee for Medicinal Products for Human Use Reference: Strontium (Protos®) - A safety update. 25 Mar 2008: at http://www.hsa.sg (CHMP) was alerted to an increasing

95 Safety and Efficacy Issues WHO Drug Information Vol 22, No. 2, 2008

Lapatinib and hepatoxicity Telbivudine and peripheral Singapore — In consultation with HSA, neuropathy the manufacturer of lapatinib (Tykerb®) Singapore — Telbivudine (Sebivo®) is has informed healthcare professionals of indicated for the treatment of HBeAg- new safety information on hepatotoxicity. positive and HBeAg-negative chronic hepatitis B in patients who have compen- From the manufacturer’s worldwide sated liver disease, evidence of viral safety database, 39 cases of hepatotoxic- replication and active liver inflammation, ity were identified, of which 38.5% of and who are nucleoside analogue naive. subjects were receiving lapatinib monotherapy while 53.8% were receiving In a pilot clinical trial, 8 cases of periph- lapatinib in combination with other eral neuropathy were reported out of the chemotherapies, such as capecitabine. 48 patients treated with telbivudine and a standard dose of pegylated interferon Majority of the key cases were from alfa-2a. The time to onset for the event clinical trials, which yielded a crude was approximately 2 to 6 months. In incidence of 0.4% for hepatobiliary events contrast, the rate of peripheral neuropa- in the entire lapatinib clinical program thy in the 2-year pivotal study with telbivu- while 7 cases of hepatotoxicity were from dine monotherapy was uncommon. spontaneous sources. There have been 13 incidences of death with reported liver- As the risk of developing peripheral related events. neuropathy appears to be increased in the telbivudine and pegylated-interferon Healthcare professionals are advised to alfa-2a combination, the manufacturer is monitor their patients’ liver functions working with the Health Sciences Agency before initiating treatment and at approxi- (HSA) to update the product information. mately monthly intervals thereafter or as clinically indicated. Tykerb® should be Reference: Peripheral neuropathy seen with discontinued and not restarted in patients the combination treatment of Sebivo® (telbivu- with severe changes in liver function. dine) with pegylated interferon alfa-2a, 17 March 2008 at http://www.hsa.sg Reference: Tykerb® (lapatinib) and new safety information on hepatotoxicity, 1 April 2008 at http://www.hsa.sg

Spontaneous monitoring systems are useful in detecting signals of relatively rare, serious and unexpected adverse drug reactions. A signal is defined as "reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually, more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information". All signals must be validated before any regulatory decision can be made.

96 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

International Nonproprietary Names for monoclonal antibodies: IFPMA proposal

This summary represents the IFPMA proposal presented to the 46th Consultation on International Nonproprietary Names (INNs) for Pharmaceutical Substances held at the World Health Organization in Geneva in April 2008. The proposal was developed by the IFPMA (International Federation of Pharmaceutical Manufacturers & Associa- tions) Biotech Working Group, which includes twenty companies, two regional and three national associations located in Europe, Japan and USA. The pioneering work of Kohler and Milstein (1) in the 1970s provided the means to produce monoclonal antibodies (MAbs) derived from a single clone of cells which bind to a single antigenic determinant with predefined specificity. This paved the way to use this class of biomolecules as diagnostic tools as well as therapeutic drug substances for treatment of cancer, auto-immune, and other diseases. Technological advances in the generation of antibodies with reduced immunogenicity permitted the development of MAb-based therapies as a major strategy in biomedicine (2). Today, more than 20 MAb-based medicines have been approved for marketing, and a further 160 MAbs were in development in 2006 (3). The appearance of the first MAb-based drugs in the late 1980s created the impetus for the WHO INN programme to establish a naming system for monoclonal antibodies in 1990/91. By 2006, more than 140 INNs had been selected for MAbs. The system was gradually expanded but the general policy for naming of MAbs remained unchanged [reviewed in (4)]. The nomenclature rules for monoclonal antibodies are complex. Furthermore, current developments in the use of different antibody types with different functions, antibody fragments and antibody glycoengineering add to this complexity. Therefore, it was decided (5) that consideration should be given to establishing a small expert group to review these developments and to make specific recommendations on INN policy for monoclonal antibodies. In order to support this process, the IFPMA has developed Proposals for principles for INNs of new monoclonal antibodies (6). This summary is intended to give a short overview on MAbs, their molecular structure and aspects relevant to their use as pharmaceutical drug substances, and to communicate and explain the IFPMA naming proposal. It should be emphasized that the additional explanations given in this paper do not necessarily represent a harmonized IFPMA position but reflect the per- sonal views of the authors.*

* The article was prepared by Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associa- tions (IFPMA) Biotech Working Group: http://www.ifpma.org/Issues/Biologicals/. Correspond- ence: Ryoko Krause, IFPMA at [email protected]

97 International Nonproprietary Names WHO Drug Information Vol 22, No. 2, 2008

Molecular structure of antibodies – binding fragments comprising one light the immunoglobulin molecule chain and the VH and CH1 parts of one heavy chain), responsible for antigen Antibodies, also called immunoglobulins, specificity and binding, and F (“fragment are a large group of closely related glyco- c crystallizable”, comprising the CH2 and proteins with a molecular weight of up to C 3 parts of two heavy chains). 150 kDa. Each immunoglobulin molecule H is composed of two identical heavy Based on the amino acid sequence dif- chains and two identical light chains, ferences in the constant part of the heavy linked together by disulfide bonds (Fig.1). chains, immunoglobulins are classed by The amino acid sequences of the amino- isotypes (e.g. human IgA, IgG, IgM, IgD, and IgE). All licensed therapeutic antibod- terminal regions, referred to as VH and VL, are highly variable and are involved in ies belong to the IgG isotype. Human antigen binding. The constant part of the IgG–Fc contains carbohydrate residues bound to residue Asn297 in each of the light chain is called CL, and the constant part of the heavy chain is sub-divided into CH2 domains, thus characterizing IgG as a glycoprotein. In addition, 15–20% of three domains CH1, CH2, and CH3. Two heavy and two light chains form a “Y- human IgG molecules have N-linked shaped” hetero-tetrameric superstructure. oligosaccharides within the Fab region (7). It consists of three structurally independ- The oligosaccharides provide important ent moieties connected by a flexible hinge recognition sites mediating a variety of region, which are termed F (the antigen- interactions (see 8) and play specific ab structural roles.

Figure 1. Structure of an IgG Molecule

98 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

Within the IgG isotype, there are four thereby increases in-vitro ADCC more different sub-classes (IgG1, IgG2, IgG3, than 50-fold. The presence or absence of and IgG4) differing in their amino acid galactose and sialic acid residues also sequence, hinge length, binding to Fc influences ADCC (12) and CDC. receptors and complement, and biological function. In development of therapeutic Several studies (e.g. 13,14) have high- monoclonal antibodies, scientists have lighted the importance of FcgR-mediated killing of target cells for the efficacy of focused on the IgG1, IgG2, and IgG4 subclasses (9). antibody treatment in cancer therapies, which represents an essential mechanism Immune effector functions and for efficacy. Modulation of IgG glycoengineering glycosylation (“glycoengineering”) which results in removal of part or all of the Antibodies specifically bind to their fucose residues in order to enhance antigens via their F fragment regions. In ab potency is considered a promising tech- general, they thereby can prevent patho- nology to enhance the efficacy of thera- gens from entering or damaging cells, peutic MAbs (15), as already demon- interfere with signal transduction medi- strated in murine xenograft models (16). ated by interactions of ligands with cell MAb-based medicines containing surface receptors, and induce cell-death glycoengineered antibodies have entered mechanisms through apoptosis or by clinical development. blocking the action of survival pathways.

In contrast to the importance of Fc inter- Furthermore, by virtue of interaction sites actions in cancer, in some disease areas located in the Fc part of IgG, antibodies (e.g. for treatment of inflammatory dis- can also stimulate removal of a pathogen eases) Fc-mediated effects can lead to or tumour cell by macrophages and other safety issues and it may be desirable to cells of the immune system. This is minimize or even eliminate Fc-mediated mediated by interaction with Fc-gamma interactions. Thus, glycosylation of receptors (FcgRs) present on the immune antibodies can be crucial for their clinical cells and eliciting antibody-dependent profile, including aspects of safety and cellular cytotoxicity (ADCC). Antibodies efficacy, and the consistency of glyco- can also trigger direct pathogen or cell sylation has to be carefully controlled. destruction by stimulating other immune responses such as the complement Monoclonal antibody production pathway (complement-dependent cyto- and heterogeneity toxicity, CDC). These effects have been According to the original Kohler-Milstein termed “immune effector functions” of technology, monoclonal antibodies are antibodies. obtained from hybridoma cells. Today, therapeutic MAbs are usually produced It has been shown (10,11) that the pres- using recombinant DNA technology. Due ence and structure of the Fc-bound to the requirement for glycosylation, all carbohydrate moieties of the IgG mol- antibody therapeutics that are currently ecule are essential for binding to a certain licensed are manufactured from mamma- subtype of FcgRs (FcgRIIIa) and promo- lian cell culture, using e.g. Chinese tion of effector functions: IgG molecules hamster ovary (CHO) and mouse mye- with an ungycosylated Fc portion retain loma (NS0 or Sp2/0) cells. Other systems little ability in activating complement and based on transgenic animals, yeast, binding to FcgRs. On the other hand, the plants, etc. are under development. lack of a fucose residue in human IgG1 Unglycosylated Fab fragments can be enhances the binding to FcgRIIIa and produced from prokaryotic systems.

99 International Nonproprietary Names WHO Drug Information Vol 22, No. 2, 2008

Manufacturing of recombinant MAbs, Lowering the immunogenicity which is a complex multi-step process, Monoclonal antibodies obtained by the requires the same high standards in original Kohler-Milstein procedure, and process development, validation and the first MAb which was licensed in 1986 control as for other recombinant thera- for use in therapy (muromonab-CD3), peutic proteins. Sound product and were murine proteins. However, rodent process knowledge (preferentially based MAbs can elicit an immunogenic re- on “quality by design” concepts) is indis- sponse referred to as human anti-mouse pensable in order to ensure and maintain antibodies (HAMA). Furthermore, thera- product quality. The safety and efficacy of peutic efficacy may be reduced by rela- antibody therapeutics, including their tively faster clearance (as compared to stability and immunogenic potential, are human antibodies) and weak effector critically dependent on post-translational functions in humans (19). Therefore, modifications such as, but not limited to, efforts were made to make MAbs more glycosylation which are highly depending “human-like” by genetically fusing rodent on the manufacturing and control charac- variable domains to human constant teristics of the process. domains (resulting in “chimeric” antibodies which still contain about 35% rodent In this context, it should be emphasized sequences). “Humanized” antibodies with that even highly purified recombinant only approximately 10% rodent se- proteins, due to the complexity of both quences have also been produced by their molecular structure and their manu- grafting only the six loops, termed facturing process, are never single and complementarity determining regions uniform molecular entities, but families of (CDRs), of the antibody sequence which closely related molecular variants (18,19). can potentially interact with the target These variations will be introduced by the molecule to a human antibody framework, manufacturing cell itself, as well as by the combined with some additional sequence production process. For an IgG antibody, optimization. These chimeric or human- it has been estimated that, even consider- ized antibodies indeed exhibit less ing only a limited number of glycoform immunogenicity, and most of the mono- variants (17), up to 108 variants are clonal antibody products presently li- theoretically possible; in fact, variability censed contain either chimeric or human- may be even greater since there may be ized antibodies. many more glycoforms than considered in this analysis (7). In contrast to the situa- More recently, methods have become tion with small, chemically synthesized available to obtain MAbs with “fully molecules, current protein-analytical human” sequence (20), either by using methods are not able to characterize phage display selection techniques, or by complex proteins completely, and the generating the antibodies in mice trans- functional impact is known only for genic for the human immunoglobulin particular attributes (or defined combina- genes. Currently, two therapeutic “fully tions of some attributes). Therefore, for human” MAbs (adalimumab, panitumu- recombinant proteins including mono- mab) are licensed, with many more being clonal antibodies manufactured by in clinical development. Alternatively, different, independently developed efforts are ongoing to reduce the immu- processes, differences in microhetero- nogenicity of chimeric MAbs by “de- geneity have to be expected whose immunization” based on in-silico identifi- impact on clinically relevant properties cation of potential linear T-cell epitopes usually cannot be predicted. which then are removed by altering the sequence. Several of these MAbs which

100 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

strictly cannot be designated as “chi- oligomeric conjugates. Several Fab frag- meric” nor “humanized” or “human” have ments have already been licensed for use entered clinical development. as drugs (e.g., abxicimab, ranibizumab, 99mTc-sulesomab). As a result of their However, even “fully human” MAbs have smaller size, antibody fragments usually a significant immunogenic potential in exhibit shorter in-vivo half-life than intact patients. The formation of antibodies may antibodies. However, their in-vivo half life be due to the presence of foreign se- can be increased by conjugation with quences or epitopes, but also to product poly(ethylene glycol)(PEG). quality issues (e.g., presence of aggre- gates) and/or patient- and disease-related Due to their exquisite antigen binding factors. Thus, even small differences in specificity, antibodies (or their Fab frag- therapeutic protein products may lead to ments) can be used for targeting cytotoxic unexpected immunogenicity. drugs, cytokines, toxins, or radio-isotopes to the desired location, e.g. tumour cells Bi-specific antibodies, antibody (22). Licensed products following this fragments, antibody conjugates principle include e.g. ibritumomab tiux- Whereas unmodified, intact antibodies etan, gemtuzumab ozogamicin, or represented the first wave of licensed (131I)tositumomab. immunotherapeutic reagents, it soon became clear that it is often desirable to The Fc part of the IgG molecule, when improve clinically relevant properties, fused genetically to otherwise short-lived such as pharmacokinetics, potency, protein sequences, can serve to extend avidity, or half-life. Among the approaches the in-vivo half-life considerably. Several to address these topics is the construc- fusion proteins relying on this concept tion of bi-specific antibodies (containing have been licensed (e.g., etanercept, two different binding specificities con- rilonacept, alefacept). nected together) which in some cases are even designated as “trifunctional” due The present policy of MAb naming to immune effector functions mediated by International Nonproprietary Names (INNs) are unique names which are the Fc part (e.g. catumaxomab). globally recognized. They are assigned to allow the clear and unambiguous identifi- It is possible to minimize Fc-mediated effects in therapeutic MAbs by selecting cation, safe prescription and dispensing IgG subclasses with low effector func- of active pharmaceutical ingredients based on molecular characteristics and tions, such as IgG2, IgG4, or IgG1 mu- tants. Another option to eliminate un- pharmacological class (23). Since initiation of the INN system in 1950, INNs wanted Fc functionalities is the use of antibody fragments obtained by proteoly- have become essential for health profes- sis of intact antibodies or by recombinant sionals as a tool for correct prescription expression of monovalent fragments and are used by drug manufacturers, regulatory authorities, authorities involved (such as Fab, Fv, or single-chain Fv frag- in reimbursement and some other inter- ments) which are devoid of the Fc part of the IgG molecule (21). Due to their ested parties. They play a key role in smaller size, these antibody fragments communication, prescription, interchange- may exhibit better pharmakokinetics for ability and reimbursement of medicines tissue (e.g., tumour) penetration. If multi- as well as pharmacovigilance. valent binding is desired to increase retention times on the target, such frag- The concept of INNs was initially devel- ments can be engineered into di- or oped for small chemical entities that can

101 International Nonproprietary Names WHO Drug Information Vol 22, No. 2, 2008

be fully characterized by physicochemical prietary Names (INNs) for Pharmaceutical means. Due to the progress in biomedical Substances held at WHO Headquarters and biotechnological research, medicinal on 22–24 May 2007 (5) that consideration products containing significantly more should be given to review these develop- complex substances of biological origin ments and to make specific recommenda- have been and will continue to be devel- tions on a revised INN policy for mono- oped. As a consequence, INNs need to clonal antibodies. be assigned for these complex products. The challenge is that these active phar- IFPMA proposals for principles maceutical ingredients (APIs) are often on INNs for new MAbs very large macromolecules which cannot With the intention of supporting this be fully characterized analytically. More- process, IFPMA has developed the over, these APIs are not single specific following ideas for principles which, from ingredients but mixtures of molecular the industry view, should preferably be species which are differently glyco- followed in the naming of new MAbs (6). sylated, or otherwise modified post- The following proposals should serve to translationally. focus attention on a number of important A systematic scheme for INNs of MAbs aspects. Proposals approved by the was implemented in the early 1990s. The IFPMA Biotech Working Group are printed in bold italic. common stem is ‘-mab’, sub-stems indicate the source of the product (e.g. -o- for mouse, -u- for human, -xi- for chi- 1. The naming convention for monoclonal antibodies should follow the meric, -zu- for humanized), and further sub-stems indicate the disease or target same policy as established for all class (e.g. -li- for immunomodulators, - (glyco)proteins. Thus, protein drug vi(r)- for viral) or tumour type (e.g. -co- for substances (including MAbs) with differences in amino acid sequence colon, -ma(r)- for mammary, -me(l)- for melanoma, -tu(m)- for miscellaneous). should always have different INNs. The prefix is chosen randomly, but should Monoclonal antibodies are glycoproteins, contribute to a euphonious and distinctive name. If necessary, a second word is and there is good reason to use the same added, indicating radiolabelling or conju- general policy as for naming of other glycosylated proteins where the INN gations, e.g. to toxins. In this case, the infix -toxa- can be inserted. Several system is well established and proved to further rules and restrictions apply (i.e., be useful for all stakeholders. avoid conflicts with trademarks and brand names). To accommodate new technical 2. IFPMA proposes to continue the use developments the system has become of the common stem –mab for monoclonal antibodies. For antibody frag- increasingly complex. Due to the increas- ments (such as F fragments), the use ing number of INNs selected for MAbs, ab difficulties have arisen especially in those of –fab instead of –mab might be considered. MAb groups which attract the biggest research interest, e.g. cancer and autoimmune diseases. As a conse- We propose to differentiate between complete (intact) antibodies and antibody quence, new INNs tend to become longer, more complicated, and there is fragments which presently are also the potential for confusion. named using the same stem –mab (e.g., abxicimab, ranibizumab). Differentiation Therefore, it was decided at the 44th would be helpful for the INN users. Consultation on International Nonpro- However, it is open for discussion

102 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

whether other distinct stems should be using designators (e.g., Greek letters, defined for products based on other details to be decided by WHO) as for immunoglobulin fragments such as Fv, other glycosylated proteins. This require- scFv, or other fragments (see 21), or ment is justified scientifically since it has whether a general stem (such as –fab) clearly been shown that differences in might be used to indicate that the product glycosylation (e.g., fucosylation, galacto- is derived from a Mab type structure. sylation, sialylation) influence immune effector functions and thus may have an 3. An invented part of the INN is still impact on clinically relevant properties. considered necessary. IFPMA pro- Consequently, MAbs with an identical poses that WHO makes efforts to amino acid sequence but a different provide related names for MAbs glycosylation pattern have to be consid- directed against the same molecular ered different drug substances and target (although these MAbs neverthe- therefore should have different INNs. less may differ in amino acid sequence, epitope specificity, immune In accordance with the naming policy for effector functions, binding constants, glycosylated proteins, MAbs with a etc.). different glycosylation pattern (or other differences in post-translational modifica- The specificity of a MAb for its antigen tions) should have distinct INNs even if (which represents the molecular target) is their amino acid sequence is the same. the most important element of information This is important because cases are characterizing a monoclonal antibody as expected where MAbs with the same a drug substance. Presently, antigen amino acid sequence, but proven or specificity is not apparent from the INNs potential differences in glycosylation are selected for MAbs. Since the number of developed which may possess different clinically validated MAb targets is limited, clinical properties. Such differences may it can be expected that there will be either be intended, e.g. in glycoengineer- several MAbs entering clinical studies or ed antibodies, or unintended but inevita- obtaining marketing approval which are ble due to the use of different, independ- directed against the same antigen – in ent manufacturing processes, e.g. in fact, this is already reality (e.g., cetuxi- subsequent-entry (stand-alone follower or mab and panitumumab both adress the biosimilar) products. epidermal growth factor (EGF) receptor although this is not evident from the 5. At the time of INN application it may respective INNs). It would help the users not yet be clear whether modification of INNs if related, although different, INNs (e.g., glycosylation) is identical or would be provided for MAbs addressing different. Therefore, monoclonal the same antigen. However, it is not antibodies made independently (i.e., suggested that the INN system should by different manufacturers using develop systematic naming principles for different processes) should generally all potential antigens, which clearly is not obtain distinct INNs. These distinct possible. INNs should have the same stem but include different designators or identifiers. 4. Consistent with the naming conven- tions for other glycoproteins, it is It should be noted that this policy in mandatory that differences in post- practice will only be efficient if WHO and translational modifications (for exam- the drug regulatory authorities agree to ple, but not limited to, the make it mandatory for the second manu- glycosylation pattern) are indicated in facturers to present their substances to the INN of MAbs. This might be done WHO and apply for a distinct INN.

103 International Nonproprietary Names WHO Drug Information Vol 22, No. 2, 2008

Manufacturers usually apply for INNs targets) which may be involved in more during early clinical development when than one indication or disease. Therefore, the final manufacturing process may still it is likely (and already reality in some be under development and the quality cases) that MAb drug substances will be profile, including the modification (e.g. used in more than one disease (e.g., glycosylation) pattern of the product to be cancer and inflammatory diseases). While commercialized, has not yet been finally it is recognized that information on the established. So, as a matter of precau- disease is useful for the physician, IFPMA tion, distinct INNs should be given at that believes that WHO should discuss time to MAbs made by different manufac- whether it is appropriate to include turers using different, independent proc- information on the disease, or rather on esses. Even if it turns out later on that the the molecular target (e.g., CD20, HER-2, glycosylation pattern of two products is etc.) in the INN. the same, the issue of having two products with identical properties but distinct In cases where the same MAb is used in INNs can be considered minor compared therapy for more than one disease (e.g., to the risk of having two products with the rituximab in non-Hodgkin lymphoma as same INN but different clinical properties well as rheumatoid arthritis), it is confus- because in this latter case, “clear identifi- ing when the INN includes information cation, safe prescription and dispensing” relating to only one of these diseases as requested by WHO (23) based on the only. Although this can also be the case INN would be impossible. with chemically synthesized, low-molecular weight drug substances, it is more This concept does not contradict the fact likely to occur with monoclonal antibody- that there may be some batch-to-batch based medicines because biopharma- variability of the glycosylation pattern, as ceuticals discovery and development is well as slight glycosylation differences based on interfering with complex after manufacturing changes in a given signaling pathways, which may be in- product. In these cases, the range of volved in multiple diseases, rather than variability is validated by the results of solely on organ pathology. Therefore, it clinical development and by the compara- should be considered to include informa- bility exercise to be performed by the tion on the antigen/molecular target (cf. manufacturer according to the ICH Q5E proposal 3 above) rather than on the guideline (24) in case of process disease in the name. changes. Thereby it is ensured that within the design space defined by these data, 7. IFPMA does not believe that more there is no adverse impact on the quality, detailed information on the mecha- safety or efficacy of the drug product. So nism of action (e.g., inhibitory, stimu- there is no need to select a distinct INN latory, etc.) has to be part of the INN to after manufacturing changes provided avoid too much complexity of the that pre- and post-change comparability names. This information should rather be is demonstrated. part of the substance description. How- ever, this should be left to WHO’s discre- 6. Generally, the INNs contain information. tion on the “pharmacological class” of the substance. Until now, this has 8. Specific information for which subtype been done for MAbs by including a of disease (e.g., kind of tumour) an sub-stem for the “disease or target” antibody drug substance is used (e.g., class. However, targeted therapies such colon, testis, ovary, etc.) is not useful as monoclonal antibodies often address because many MAbs in oncology may be biological mechanisms (and molecular used for several tumour types. Naming

104 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

according to the first indication (which other pegylated proteins, pegylated MAbs often will turn out not to be the most and Fabs should obtain the prefix “peg-”. important) would be misleading. IFPMA Differences in conjugation (e.g., site of proposes to remove this information from modification, conjugate chemistry, linker the INN. chemistry, chain length of polymer, etc.) would require differentiation as for other 9. In order to simplify the INNs for types of modification. As far as possible, MAbs, IFPMA also considers INN the naming of antibody conjugates should differentiation dependent on the follow the naming convention applied to “source of product” (human, mouse, non-antibody conjugates. chimeric, humanized, etc.) no longer necessary. This distinction is scientifi- 11. Fusion constructs containing parts cally questionable due to the fact that of an immunoglobulin molecule ge- there are emerging approaches to design netically fused to another sequence MAb sequences in silico, in order to have to be treated as a new protein reduce immunogenicity, for removal of T- and should obtain individual INNs. cell epitopes. The resulting MAbs can WHO should discuss whether it is more neither be classified “murine” or appropriate to follow the policy for MAb “chimerized”, “humanized”, or “human”. naming, or for non-antibody proteins in The same principle applies to MAbs these cases. generated by, for example, phage display. This type of information should be part of In the present INN policy (4), fusion the description of the substance rather constructs containing the immunoglobulin than the INN. Fc part connected to a receptor molecule (or part of a receptor molecule) have Proposals 8 and 9 are intended to sup- been designated with the stem –cept port simplification of the MAb INNs. This (e.g., alefacept, abatacept, rilonacept). can only be done if some of the above From these names, it is not apparent that mentioned informative parts — which the products contain part of an immu- according to the present policy are noglobulin sequence. In future, there may included in the names — will be removed. be fusion products which contain e.g. Fc Information on the “kind of tumour” as sequences fused to other peptide (but not well as on the “source of product” both necessarily receptor) sequences. While it are scientifically questionable and can is evident that each of these products will even be misleading for the user, and need a distinct INN, it is proposed to therefore need not necessarily be part of consider whether the presence of anti- the name itself. However since this body (Fc) sequences should be indicated information certainly is helpful in some in the INN. situations, it should be retrievable within the substance description which is Conclusion associated with the INN. Due to technological progress and the increasing number of MAb-based drugs 10. Distinct names should be assigned under development and on the market, a to derivatives of antibodies including revision of the present policy for INNs of e.g. bispecific antibodies, antibody- MAbs should be performed. With the peptide or antibody-toxin conjugates, proposals described in this paper, IFPMA and radio-labelled antibodies. INNs for would like to support this process and conjugates might be composed (e.g. as contribute to the establishment of a MAb two separate words) from the names naming system that is able to accommo- assigned to the individual components. In date the recent and emerging technical accordance with the naming policy for developments in the field of monoclonal

105 International Nonproprietary Names WHO Drug Information Vol 22, No. 2, 2008

antibodies, while at the same time being 10. Tao, M.H., Morrison, S.L. Studies of as clear and simple as possible. aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and References effector functions mediated by the human IgG constant region. J. Immunol. 1989; 143:2595– 1. Kohler, G., Milstein, C. Continuous cultures 2601. of fused cells secreting antibody of predefined 11. Mimura, M., Sondermann, P., Ghirlando, specificity. Nature 1975; 256:495–497. R., Lund, J., Young, S.P., Goodall, M., Jefferis, R. Role of oligosaccharide residues of IgG1- 2. Brekke, O.H., Sandlie, I. Therapeutic Fc in FcgRIIb binding. J. Biol. Chem. 2001; antibodies for human diseases at the dawn of 276:45539-45547. the twenty-first century. Nature Revs. Drug Discovery 2003; 2:52–62. 12. Scallon, B.J., Tam, S.H., McCarthy, S., Cai, A.N., Raju, T.S. Higher levels of sialylated 3. PhRMA (Pharmaceuticals Research and Fc glycans in immunoglobulin G molecules Manufacturers of America). Medicines in can adversely impact functionality. Mol. development: Biotechnology. 2006. http:// Immunol. 2007; 44:1524–1534. www.phrma.org/files/Biotech%202006.pdf. 13. Cartron, G., Dacheux, L., Salles, G., Solal- 4. WHO Programme on International Nonpro- Celigny, P., Bardos, P., Colombat, P., Watier, prietary Names. International Nonproprietary H. Therapeutic activity of humanized anti- Names (INN) for biological and biotechnologi- CD20 monoclonal antibody and polymorphism cal substances (a review). INN Working in IgG Fc receptor FcgRIIIa gene. Blood 2002; Document 05.179. 2007. 99:754–758. 14. Clynes, R.A., Towers, T.L., Presta, L.G., 5. WHO Programme on International Nonpro- Ravetch, J.V. Inhibitory Fc receptors modulate prietary Names. 44th Consultation on Interna- in vivo cytotoxicity against tumor targets. tional Nonproprietary Names (INNs) for Nature Med. 2000; 6:443–446. Pharmaceutical Substances, Executive Summary. 2007. http://www.who.int/medi- 15. Umana, P., Jean-Mairet, J., Moudry, R., cines/services/inn/FinalConsolidated Amstutz, H., Bailey, J. Engineered glycoforms ExecSum44INN.pdf [cited 2008 Apr 24]. of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxicity. 6. IFPMA. Proposal to the WHO INN Expert Nature Biotechnol. 1999; 17:176–180. Group: Principles for naming of new monoclonal antibodies. 2008. http://www.ifpma.org/ 16. Friess, T., Gerdes, C., Nopora, A., Patre, fileadmin/templates/ifpmaissues/pdfs/ M., Preiss, S., van Puijenbroek, E., Schuell, 2008_03_21_IFPMA_Proposal_for_naming_of_ C., Bauer, S., Umana, P., Klein, C. GA101, a new_monoclonals.pdf [cited 2008 Apr 24]. novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death 7. Jefferis, R. Glycosylation of recombinant induction, mediates superior efficacy in a antibody therapeutics. Biotechnol. Prog. 2005; variety of NHL xenograft models in compari- 21:11–16. son to rituximab. Blood. 2007; 110:2338. 8. Arnold, J.N., Wormald, M.R., Sim, R.B., 17. Kozlowski, S., Swann, P. Current and Rudd, P.M., Dwek, R.A. The impact of future issues in the manufacturing and glycosylation of the biological function and development of monoclonal antibodies. Adv. structure of human immunoglobulins. Annu. Drug Delivery Revs. 2006; 58:707–722. Revs. Immunol. 2007; 25:21–50. 18. ICH Q6B Guideline: Specifications: test 9. Salfeld, J.G. Isotype selection in antibody procedures and acceptance criteria for engineering. Nature Biotechnol. 2007; biotechnological products, 1999, http:// 25:1369–1372. www.ich.org/LOB/media/MEDIA432.pdf [cited 2008 Apr 16].

106 WHO Drug Information Vol 22, No. 2, 2008 International Nonproprietary Names

19. Walsh, G., Jefferis, R. Post-translational 22. Schrama, D., Reisfeld, R.A., Becker, J.C. modifications in the context of therapeutic Antibody targeted drugs as cancer therapeu- proteins. Nature Biotechnol. 2006; 24:1241- tics. Nature Revs. Oncology 2006; 5:147-159. 1252. 23. World Health Organization. Guidelines on 20. Presta, L.G. Engineering of therapeutic the use of International Nonproprietary Names antibodies to minimize immunogenicity and (INNs) for pharmaceutical substances, WHO/ optimize function. Adv. Drug Delivery Revs. PHARM S/NOM 1570, 1997. 2006; 58:640-646. 24. ICH Q5E Guideline: Comparability of biotechnological/biological products subject to 21. Hudson, P.J., Souriau, C. Engineered changes in their manufacturing rocess, 2005, antibodies. Nature Med. 2003; 9:129-134. http://www.ich.org/LOB/media/MEDIA1196.pdf [cited 2008 Apr 24].

107 WHO Drug Information Vol 22, No. 2, 2008

Regulatory Action and News

Dydrogesterone withdrawn mg daily for up to five days). Lumiracoxib for commercial reasons was not widely used in Australia until it was included on the Pharmaceutical United Kingdom — Dydrogesterone Benefits Schedule (PBS) in July 2006. (Duphaston ®) is to be withdrawn from the market from March 2008 for commer- Following the evaluation of trial data cial reasons. Dydrogesterone was li- showing that the efficacy of a 100 mg censed for use in several indications, daily dose was comparable to that of the including threatened or recurrent miscar- 200 mg dose, a 100 mg tablet was riage, dysfunctional uterine bleeding, and registered for use in Australia in June hormone replacement therapy. 2007 for the relief of symptoms of osteoarthritis. In the 12 month period up to the A Public Assessment Report has re- end of July 2007, 567,903 prescriptions viewed evidence for the efficacy of for lumiracoxib were dispensed in Aus- progesterone and dydrogesterone in the tralia. maintenance of pregnancy in women with threatened miscarriage or recurrent In March 2007, the first Australian report miscarriage. of serious hepatotoxicity associated with the use of lumiracoxib was received. For several decades, progesterone and Concerns about this case stimulated a progestogens (such as dydrogesterone) priority review of the general safety profile have been used to maintain early preg- of lumiracoxib, with a focus on hepato- nancy. However, this practice seems to toxicity. have been based on theoretical consid- erations rather than robust evidence of By the time of the Australian Adverse efficacy. Although the methodological and Reactions Advisory Committee (ADRAC) ethical difficulties associated with con- meeting on 10 August, the Therapeutic ducting efficacy trials in these indications Goods Administration (TGA) had received need to be considered, the quality of eight reports of serious liver injury associ- much of the evidence is generally poor ated with the use of lumiracoxib. There relative to today’s standards. were also three reports of minor increases in liver enzymes. There were five Reference: Medicines and Healthcare reports of hepatic failure, including two products Regulatory Agency (MHRA) informa- fatalities and two liver transplants, and an tion release. http://www.mhra.gov.uk/ Safetyinformation additional three reports of severe jaun- dice or acute hepatitis without liver failure. Withdrawal of lumiracoxib ADRAC was informed of a further three Australia — Lumiracoxib is a selective overseas reports of hepatic failure with COX-2 inhibitor, which was registered in lumiracoxib, all from South America. Australia in 2004 for the symptomatic ADRAC also reviewed data provided by relief of osteoarthritis (at 200 mg daily) the sponsor of lumiracoxib regarding liver and for the treatment of acute pain and abnormalities seen in the clinical trial pain due to primary dysmenorrhoea (400 programme.

108 WHO Drug Information Vol 22, No. 2, 2008 Regulatory Action and News

At the August meeting, it was known that The TGA has required testing of all a 100 mg dose of lumiracoxib had been heparin containing products in Australia registered recently in Australia. However, since March 2008, following the identifica- the Committee was concerned there was tion of a contaminant known as "over- insufficient evidence for an adequate sulphated chondroitin sulphate (OSCS)" margin of safety with the 100 mg daily implicated in several severe allergic dose because of the possibility that the reactions in the USA and Europe. hepatotoxicity of lumiracoxib may be idiosyncratic; that lower doses may be As a result of this testing contamination hepatotoxic in specific populations such with OSCS has been detected in five as the elderly, low-weight individuals, or batches of the low molecular weight those with other underlying disease; or heparin product Clexane®. These that the 100 mg daily dose may be batches have been quarantined pending exceeded by patients seeking more pain further assessment. relief. ADRAC also considered that the apparent rate of severe liver injury with To date, there have been no reports of lumiracoxib appeared greater than for adverse events in Australia of the type other marketed nonsteroidal anti-inflam- reported in the United States associated matory drugs. with heparin products. Nevertheless, the TGA has decided to quarantine the After the above review and advice from affected batches so no patients are put at ADRAC that the risks of lumiracoxib undue risk at this time. outweighed its benefits, the TGA acted immediately to cancel the registration of Responses from regulatory agencies all forms of lumiracoxib in Australia, on around the world have varied, with some the grounds that failure to cancel the agencies initiating recalls and others registration would create an imminent risk continuing to allow contaminated product of death, serious illness or serious injury. to remain in the market, based on the Following the cancellation, the TGA view that in many clinical settings the advised that all patients should stop benefits of continued use of these blood taking lumiracoxib immediately, and thinning agents outweigh the possible should be assessed by their doctor for risks from contamination. any evidence of liver damage (see TGA website at www.tga.gov.au/alerts/ Reference: Therapeutic Goods Administration prexige.htm) Alert, 22 April 2008. http://www.tga.gov.au/ alerts/medicines/clexane.htm Extracted from Australian Adverse Drug Sweden — On 23 April 2008, the Medical Reactions Bulletin, Volume 27, Number 2, Products Agency decided to recall the April 2008 contaminated batches of enoxaparin (Klexane®) found on the Swedish market. Enoxaparin contamination: The level of contamination is low and the batches recalled recall was made as a precautionary measure. Australia —The Therapeutic Goods Administration (TGA) has recalled five During January and February 2008 batches of the anticoagulant medicine Baxter recalled almost all of their heparin enoxaparin (Clexane®) due to the detec- products from the US market after reports tion of an impurity in the affected batches. on serious adverse events. At the begin-

109 Regulatory Action and News WHO Drug Information Vol 22, No. 2, 2008

ning of March 2008, the US Food and Xyntha® is licensed for the control and Drug administration (FDA) announced prevention of bleeding, which can occur that the adverse events were associated spontaneously or after an accident or with the presence of an unknown heparin- injury in patients diagnosed with like impurity that could only be detected hemophilia A. This recombinant Factor with new analytical methods presented on VIII is produced without additives from the FDA website. human or animal material, which further minimizes any risk of infection from the The Medical Products Agency decided product. that all Companies supplying heparin products for the Swedish market should In clinical trials, Xyntha® was shown to test their products for this specific con- be effective at preventing or controlling tamination. A few batches of the low bleeding, including preventing bleeding in molecular weight heparin, Klexane®, surgery, for hemophilia A patients. Gener- were found to be contaminated with low ally, the most frequently reported adverse levels of the same impurity as in the reaction was headache. Most adverse unfractionated heparin detected in the reactions reported in either study were USA, i.e. oversulphated chondroitin considered mild or moderate in severity. sulphate (OSCS). Therefore, the Medical In addition, two of 89 individuals who Products Agency decided to recall these received 50 days of treatment with contaminated batches as a precautionary Xyntha®, developed factor VIII inhibitors, measure. which are antibodies that counteract treatment with factor VIII. No reports of similar severe adverse reactions as seen in the USA have been Reference: FDA News, 21 February 2008 at reported to the MPA. The batches of http://www.fda.gov Klexane® that have not been withdrawn can be used according to the approved Esomeprazole magnesium indications. They do not contain any approved for children impurity. United States of America — The Food Reference: Medical Products Agency, 29 April and Drug Administration (FDA) has 2008. http://www.lakemedelsverket.se/Tpl/ approved esomeprazole magnesium NewsPage____7312.aspx (Nexium®) for short-term use in children 1–11 years of age for the treatment of Recombinant antihemophilic gastroesophageal reflux disease (GERD). factor approved The agency approved Nexium® in two forms, a delayed-release capsule and United States of America — The Food liquid form, in 10 mg or 20 mg daily for and Drug Administration (FDA) has children 1–11 years old compared to 20 licensed a treatment for hemophilia A, a mg or 40 mg recommended for pediatric rare, hereditary blood-clotting disorder patients 12–17 years of age. that affects approximately 15 000 individuals, almost exclusively males, in the Children prescribed this drug should be United States. monitored by their physicians for any adverse drug reactions. The new treatment, called Xyntha® Antihemophilic Factor (Recombinant) Esomeprazole magnesium is part of a Plasma/Albumin Free, is a genetically class of drugs known as proton pump engineered version of factor VIII inhibitors (PPIs). PPIs decrease the

110 WHO Drug Information Vol 22, No. 2, 2008 Regulatory Action and News

amount of acid produced in the stomach in the United States would likely be and help heal erosions in the lining of the infected at least once with rotavirus by esophagus known as erosive esophagitis. age 5. There are many different strains of rotavirus. The vaccine protects against FDA approved the use of esomeprazole rotavirus gastroenteritis caused by the magnesium in patients 1 to 11 years for G1, G3, G4, and G9 strains. short-term treatment of GERD based upon the extrapolation of data from The most common adverse reactions previous study results in adults to the reported during clinical trials were fussi- paediatric population, as well as safety ness, irritability, cough, runny nose, fever, and pharmacokinetic studies performed in loss of appetite and vomiting. paediatric patients. In one study, 109 patients 1-11 in age, diagnosed with To help ensure that Rotarix® does not GERD, were treated with esomeprazole increase the risk of intussusception, its magnesium once-a-day for up to eight manufacturer conducted a study of more weeks to evaluate its safety and tolerabil- than 63 000 infants. In that study, there ity. Most of these patients demonstrated was no increase in the risk of intussus- healing of their esophageal erosions after ception in those who received Rotarix® eight weeks of treatment. (31 673 infants) compared to those who received placebo (31 552 infants). The most common adverse reactions in children treated with esomeprazole Increased rates of convulsion and pneu- magnesium were headache, diarrhea, monia-related deaths were observed in abdominal pain, nausea, gas, constipa- the Rotarix® recipients in the intussus- tion, dry mouth and sleepiness. The ception study, however these events were safety and efficacy of Nexium® has not not observed in other studies conducted been established in children less than by the manufacturer. Although the FDA one year of age. has concluded that the available data do not establish that these events are related Reference: FDA News, 28 February 2008 at to the vaccine, the agency has requested http://www.fda.gov the manufacturer to conduct post-marketing safety studies involving more than Rotavirus vaccine approved 40 000 infants to provide additional safety information. United States of America — The Food and Drug Administration (FDA) has Reference: FDA News, 3 April 2008 at http:// announced the approval of Rotarix®, the www.fda.gov second oral US licensed vaccine for the prevention of rotavirus, an infection that causes gastroenteritis (vomiting and New version of genetically diarrhea) in infants and children. Rotarix engineered Factor VIIa is a liquid and given in a two-dose series approved to infants from 6–24 weeks of age. United States of America — The Food Although the disease is usually self- and Drug Administration (FDA) has limiting, rotavirus causes about 2.7 million approved a new formulation of the geneti- cases of gastroenteritis in US children cally engineered version of Factor VIIa, a each year — about 55 000 to 70 000 of plasma protein essential for the clotting of those require hospitalization; and be- blood. The new formulation allows the tween 20 and 60 deaths are attributed to product to be stored at room temperature it. Without vaccination, nearly every child for up to two years.

111 Regulatory Action and News WHO Drug Information Vol 22, No. 2, 2008

The new formulation of NovoSeven The most commonly observed adverse Coagulation Factor VIIa (Recombinant)® reactions with NovoSeven RT® are fever, —contains sucrose and L-Methionine, bleeding, injection site reaction, joint which allow for storage at room tempera- discomfort, headache, elevations or falls ture. in blood pressure, nausea, vomiting, pain, swelling, and rash. Some elderly patients NovoSeven RT uses include treatment of experienced an increased risk of arterial hemophilia A or B; treatment of bleeding clotting when they were treated with and prevention of surgical bleeding in NovoSeven RT® outside of its approved patients with congenital Factor VII defi- indications. ciency; and prevention of surgical bleeding in patients with acquired hemophilia. Reference: FDA News, 9 May 2008 at http:// www.fda.gov

112 WHO Drug Information Vol 22, No. 2, 2008

International Pharmacopoeia

Role of The International tory product compliance, the following Pharmacopoeia in quality principles should be applied: assurance • the interpretation of a monograph must be in accordance with all general In the pharmaceutical sense, a pharma- requirements and testing methods, copoeia is an official, legally binding texts, or notices pertaining to it; publication containing recommended quality specifications for the analysis and • a product is not of pharmacopoeial determination of drug substances, spe- quality unless it complies with all the cific dosage forms, excipients and fin- requirements stated. ished drug products. A quality specifica- tion is a set of appropriate tests which will There is a practical distinction between confirm the identity and adequate purity pharmacopoeial standards and manufac- of the product, ascertain the strength or turers’ release specifications, although amount of the active substance and, both comprise sets of tests to which a when needed, performance characteris- given product should conform. Release tics. General requirements are also given specifications are applied at the time of in the pharmacopoeia on important manufacture of a pharmaceutical product subjects related to drug quality, such as to confirm its appropriate quality but they microbiological purity, dissolution testing, also need to have a predictive value, to or stability. support the notion that the manufacturer is responsible for the product during its The underlying principles of a pharmaco- entire shelf-life. In many cases, pharma- poeia are that pharmaceutical substances copoeial monographs are based on the and products intended for human use specifications developed by the manufac- should be manufactured at sites that are turers of innovator products. adequately equipped, dispose of appropriate professional and technical knowl- Therefore, pharmacopoeial specifications edge and are operated by qualified staff. are not used to launch innovator products General rules of appropriate pharmaceu- because the manufacturer’s quality tical manufacture are contained in the specifications will be evaluated by the good manufacturing practices (GMP) competent regulatory authorities using guidelines recommended by WHO (1) rigorous scientific assessment in conjunc- and/or those laid down by the competent tion with pre-clinical and clinical safety national or regional authority in the and efficacy data. It is important to note country of manufacture. that the regulatory focus has been shifting from finished dosage form quality control Protection provided by compendial to the control of the whole complex of standards will depend not only on techni- processes and procedures involved in the cal content but also to a great extent on manufacture of both active pharmaceuti- how they are used in the context of other cal ingredients (APIs) and finished dos- control measures. When pharmacopoeial age forms. The objective of a regulatory standards are used to establish regula- approval nowadays is to ensure that the

113 The International Pharmacopoeia WHO Drug Information Vol 22, No. 2, 2008

manufacturer has built quality into the necessarily identify all possible danger- product from A to Z. In the case of a ous impurities. Pharmacopoeial methods multisource (generic) medicine, well are usually designed to catch the impuri- resourced regulatory authorities require ties that are likely to occur during the that it should contain the same active route of synthesis that has been utilized ingredients as the innovator drug and: by the originator. In case of a different route of synthesis or accidental contami- • be identical in strength, dosage form, nation with other chemicals, it may not and route of administration necessarily pick up impurities even if they • have the same use indications pose a danger to health. This is why well resourced regulatory authorities never • be bioequivalent (as a marker for base marketing authorization of therapeutic interchangeability) multisource (generic) products on quality control testing based on pharmacopoeial • meet the same batch requirements for monographs alone. In fact, pre-marketing identity, strength, purity and quality quality control testing has diminished • be manufactured under the same strict constantly and more accent is put on standards of GMP required for innovator market surveillance after the product is products. released onto the market.

In the case of multisource (generic) Pharmacopoeial monographs help to medicines, which are formulated after verify the quality and, in the case of patents and other exclusivity rights multisource (generic) medicines, they expire, pharmacopoeial monographs are may indicate pharmaceutical interchange- important as they enable manufacturers ability with the originator product. to develop products to meet the requirements of pharmacopoeial standards (both Beginnings and history of for APIs and finished dosage forms) The International Pharmacopoeia rather than elaborate their own specifica- The history of The International Pharma- tions. It should be noted that not all copoeia dates back to 1874 when the pharmacopoeias present monographs need to standardize terminology and to (quality standards) for finished dosage specify dosages and composition of forms. drugs led to attempts to produce an international pharmacopoeial compen- Pharmacopoeial standards should be dium. A first conference, called by the used in the framework of all regulatory Belgian Government and held in Brussels measures such as good manufacturing in 1902, resulted in the Agreement for the practice (GMP) inspection of the manu- Unification of the Formulae of Potent facture of active pharmaceutical ingredi- Drugs, which was ratified in 1906 by 19 ents and finished dosage forms, and countries. A second agreement, the scientific assessment of all quality specifi- Brussels Agreement, was drawn up in cations, interchangeability data and 1925 and ratified in 1929. This 41-article labelling information. Their greatest value agreement stipulated that the League of is revealed during post-marketing surveil- Nations would be responsible for the lance of the quality of multisource (ge- administrative work to produce a unified neric) medicines. pharmacopoeia, and a permanent secretariat of an international organization Pharmacopoeial standards have also would coordinate the work of national certain limitations. For example, testing pharmacopoeial commissions. General using pharmacopoeial methods will not principles for the preparation of galeni-

114 WHO Drug Information Vol 22, No. 2, 2008 The International Pharmacopoeia

International Pharmacopoeia milestones

1874 Discussion on Unification of terminology and composition of drugs

1902 First Conference organized by the Government of Belgium

1906 Agreement on Unification of the Formulae of Potent Drugs ratified by 19 states

1925 Brussels agreement (signed 1929)

1937 First meeting - Health Organization of the League of Nations

1947 Interim Commission of WHO takes up health-related work of League of Nations

1948 First World Health Assembly (WHA) establishing the Expert Commit tee on Unification of Pharmacopoeias

1950 WHA approved publication of Pharmacopoeia Internationalis

2006 Publication of 4th edition of The International Pharmacopoeia (3) cals, maximal doses, nomenclature, and tinue the work of the League’s Technical biological testing of arsenobenzones Commission. In 1948 the First World were included in the articles of this Health Assembly approved the establish- agreement, as was a table of dosage ment of the Expert Committee by the strengths and descriptions for 77 drug Interim Commission. In 1951 this became substances and preparations. the Expert Committee on the International Pharmacopoeia; and subsequently, in In response to repeated calls from phar- 1959, the Expert Committee on Specifica- maceutical experts in various countries tions for Pharmaceutical Preparations. that the Brussels Agreement be revised The panel of experts serving this Commit- and extended to cover an international tee was named the WHO Expert Advisory pharmacopoeia, the Health Organization Panel on the International Pharmaco- of the League of Nations set up a Techni- poeia and Pharmaceutical Preparations. cal Commission of Pharmacopoeial Experts in 1937. This first committee Managing The International comprised seven experts from Belgium, Pharmacopoeia Denmark, France, the Netherlands, Work on The International Pharmaco- Switzerland, United Kingdom, and United poeia is carried out in collaboration with States of America. members of the WHO Expert Advisory Panel on the International Pharmaco- In 1947 the Interim Commission of WHO poeia and Pharmaceutical Preparations took over the work on pharmacopoeias as well as with specialists from the previously undertaken by the Health pharmaceutical industry and other institu- Organization of the League of Nations, tions. This is followed by consultation with and set up an Expert Committee on the national and regional pharmacopoeias Unification of Pharmacopoeias to con- and a working procedure based on wide

115 The International Pharmacopoeia WHO Drug Information Vol 22, No. 2, 2008

international consultation. The specifica- Step 7: Conduct laboratory testing, tions and general methods included in development and validation of QC specifi- The International Pharmacopoeia benefit cations. from an international worldwide validation process, using a global network of exper- Step 8: Support WHO Collaborating tise. This is undertaken with a view to Centre in the establishment of Interna- serve all 193 WHO Member States, the tional Chemical Reference Substances. global market and increasing trade around the world. This is a major differ- Step 9: Follow the consultative process: ence with other pharmacopoeias that send copies of draft specifications to provide control specifications for the Expert Advisory Panel and to specialists medicines sold within their country or for comments. region. Step 10: Discuss comments with contract Development of monographs for inclusion laboratories and WHO Collaborating in The International Pharmacopoeia Centres. Conduct additional laboratory testing to verify and/or validate specifica- Procedure tions.

Step 1: Identify specific pharmaceutical Step 11: Hold a consultation to discuss products for which quality control (QC) the comments and test results received specifications need to be developed, as feedback. obtain confirmation from all WHO parties concerned (e.g. Department of Medicines Step 12: Re-circulate draft monograph for Policy and Standards, Prequalification comments. project team and specific disease pro- grammes). Step 13: Repeat step 10.

Step 2: Provide contact details for manu- Step 14: Present final draft to the WHO facturers of the above products in col- Expert Committee on Specifications for laboration with all parties concerned. Pharmaceutical Preparations for possible formal adoption (for example, see the Step 3: Contact manufacturers to request Committee report from 2006, reference 6) provision of QC specifications and sam- . ples. If not adopted, repeat steps 11–13.

Step 4: Identify and contact QC laborato- The aim within this process is to keep the ries to collaborate in the project (2–3 number of reference standards to a laboratories depending on how many minimum, thus balancing the cost of pharmaceutical products have been analysis with identification of potential identified in step 1. Contract for laboratory health risks for users. work. Advantages of The International Step 5: Prepare the contract for drafting Pharmacopoeia the specifications and undertaking the Unlike national (and regional) pharma- necessary laboratory work. copoeias The International Pharmaco- poeia has no determined legal status and Step 6: Search for information on QC WHO Member States are free to adopt specifications available in the public and incorporate it, either in part or in domain. whole, into national legislation. Advan-

116 WHO Drug Information Vol 22, No. 2, 2008 The International Pharmacopoeia

tages of The International Pharmaco- substances, 183 monographs on dosage poeia are: forms (capsules, injections, tablets and tinctures) and 84 tests, methods, and • International validation of specifications general requirements. through an independent scientific process. A large number of national pharmacopoeias and official lists were examined • Input from WHO Collaborating Centres and assistance was also obtained from and national drug quality control labora- the International Pharmaceutical Federa- tories in the six WHO regions of Africa, tion (FIP) to determine the selection of the Americas, Eastern Mediterranean, substances and products to be described Europe, South-East Asia and Western in the pharmacopoeia. Pacific. Second edition • Collaboration with manufacturers The second edition was published in around the world, especially for new 1967 as Specifications for the Quality projects where no public standards Control of Pharmaceutical Preparations. exist. The selection of monographs and appen- • Collaboration with standard-setting dices was based largely on the availabil- organizations and parties, including ity, at the time, of specifications intended regional and national pharmacopoeias. for publication in national pharmacopoeias and in other volumes of specifica- • Networking and close collaboration with tions for pharmaceutical quality control. WHO Member States and drug regula- Specifications for 162 pharmaceutical tory authorities. preparations not included in the first edition were introduced in the second • Maintaining minimum cost of analysis edition, while 114 monographs were through use of robust test methods and deleted, based on feedback from the first minimum number of references stand- edition. New analytical methods were ards. also added. • Input and feedback from other WHO activities, such as the WHO/UNICEF/ Third edition World Bank Prequalification Project. In 1975, The International Pharmaco- poeia was re-focused on the needs of • Free for use by all WHO Member developing countries and recommended States. simple, classical chemical techniques that had been demonstrated as sound. Priority Published editions of was given to medicines that were widely The International Pharmacopoeia used throughout the world and medicines important to WHO public health pro- First edition grammes, also targeting those sub- The first edition, published with the aim of stances likely to contain impurities arising creating a worldwide, unified pharmaco- from degradation or due to difficulties in poeia, relied on collaboration with na- manufacture. Robust analytical test tional pharmacopoeia commissions for its methods and procedures were preferred preparation. It was published in two whenever applicable without compromis- volumes (1951 and 1955) and a supple- ing public health. A flexible approach was ment (1959) in English, French and employed to facilitate accessibility of Spanish, and was also translated into control specifications for less well German and Japanese. Altogether, it equipped national quality control labora- included 344 monographs on drug tories. Since 1979, the medicines appear-

117 The International Pharmacopoeia WHO Drug Information Vol 22, No. 2, 2008

ing in The International Pharmacopoeia on Impurities arose from the inclusion of have been selected from the WHO Model information at the end of certain new List of Essential Medicines. monographs for antiretroviral substances. Such lists of known and potential impuri- The five volumes of the third edition ties that have been shown to be control- contained 62 general methods of analysis led by the tests in a monograph are likely and requirements, quality specifications to be included more widely in future. for 255 active pharmaceutical ingredients — the majority of essential drug sub- Most importantly, a new series of mono- stances in the WHO Model List of Essen- graphs has been added for antiretrovirals. tial Medicines — 65 quality specifications These monographs have been developed for pharmaceutical excipients, and 67 as part of the WHO strategy to make finished dosage forms. quality antiretroviral medicines widely available. Such specifications support the Fourth edition joint WHO/UNICEF/World Bank Prequali- The fourth edition of The International fication Project managed by WHO (3). Pharmacopoeia was published in 2006 These new monographs provide an (2). It comprises two volumes: General element of choice in relation to test Notices and monographs for pharmaceu- methods used for identification and, tical substances (A to O) are to be found where possible, a titration method for in Volume 1 and the remaining mono- assay, in line with established policy. graphs for pharmaceutical substances (P- However, in order to provide adequate X), together with those for dosage forms control of impurities, it has been found and radiopharmaceutical preparations, necessary to place reliance on HPLC. methods of analysis and the reagent sections are to be found in Volume 2. CD-ROM The fourth edition was published simulta- This new edition consolidates the texts of neously both in print and on CD-ROM (2). the five separate volumes of the third This provides users of The International edition and includes new monographs for Pharmacopoeia with a choice of format antiretrovirals together with updates and with which to consult the publication revisions of the existing, previously depending on the circumstances and the published texts. Significant changes and type of enquiry. The response from users improvements have been made in the of the CD-ROM has demonstrated the presentation, cross-referencing to general usefulness of making the publication methods. available electronically. The simplified structure of the fourth edition and the The new notice on Definition, for exam- improved functionality of the CD-ROM will ple, serves to define dosage forms as facilitate both reading and searching text. being manufactured with active ingredients of pharmacopoeial quality and to Future role of The International clarify the mandatory status of certain Pharmacopoeia statements in monographs. The new Work is in progress on the preparation of notice on Manufacture governs the new monographs for antiretroviral sub- interpretation of statements included stances, the associated dosage forms under this heading in monographs such and for a number of fixed-dose combina- as the general monographs for dosage tion products for the treatment of HIV/ forms, the monographs for the different AIDS, malaria and tuberculosis. Special grades of water and certain other indi- attention is also being given to paediatric vidual monographs. The need for a notice formulations.

118 WHO Drug Information Vol 22, No. 2, 2008 The International Pharmacopoeia

Revision of monographs is also continu- gives advice on good manufacturing ing to improve specifications, for exam- practices and other regulatory issues, ple, by providing better means of impurity following the underlying principle that control or by the addition of a dissolution quality must be built into a product from test. Additions and revisions to the fourth the very beginning of the manufacturing edition will be made available at appropri- process. ate intervals. There is also a close link with the Interna- Meanwhile, attention is drawn to the tional Nonproprietary Names (INN) WHO Medicines website (htpp:// programme which is responsible for www.who.int/medicines), where texts of naming new pharmaceutical entities. The monographs adopted by the Expert lists of International Nonproprietary Committee on Specifications for Pharma- Names are published in a regular manner ceutical Preparations are provided (3). The whole area of work is overseen together with other detailed information. by the WHO Expert Committee on Speci- fications for Pharmaceutical Preparations. International Chemical The WHO Expert Committee on Specifi- Reference Substances cations for Pharmaceutical Preparations International Chemical Reference Sub- is an advisory body on quality assurance stances (ICRS) are primary chemical to WHO and its Member States. Advice reference standards. They are supplied and recommendations provided by this for use in physical and chemical tests and Expert Committee are intended to support assays described in the specifications for national and regional authorities (in quality control of drugs published in The particular drug regulatory authorities), International Pharmacopoeia or proposed procurement agencies, and international in draft monographs. The ICRS may be bodies and institutions such as the Global used to calibrate secondary standards. Fund, and international organizations such as UNICEF, to combat problems of Analytical data on ICRS are given in counterfeit and substandard medicines certificates enclosed with the reference and underpin important WHO initiatives. substances. ICRS may also be used in tests and assays not described in The Conclusion International Pharmacopoeia. The re- The role of WHO in quality assurance of sponsibility for assessing the suitability of medicines, especially for those countries the reference substances then rests with that have no or little means to develop the user. their own quality control specifications, is important. WHO has numerous activities For ordering information, please visit the to support Member States such as website of the WHO Collaborating Centre creating nomenclatures and developing for Chemical Reference Standards: http:// guidance, while also delivering training www.apl.apoteket.se/who. courses and workshops on various topics of quality assurance to build national Links to other WHO activities capacity to regulate medicines. The An important feature of The International International Pharmacopoeia in conjunc- Pharmacopoeia is that it forms a basic tion with International Chemical Refer- element of quality assurance activities. ence Substances are regarded as essen- WHO gives advice on the establishment tial tools in the overall framework of and management of national quality quality control and quality assurance of control laboratories, prepares guidelines pharmaceuticals, thus contributing to the on functioning, publishes guidance and safety and efficacy of drugs.

119 The International Pharmacopoeia WHO Drug Information Vol 22, No. 2, 2008

References 3. Prequalification Programme. Web site: http://mednet3.who.int/prequal/ 1. World Health Organization. Quality assurance of pharmaceuticals. A compendium of 4. World Health Organization. Expert Commit- guidelines and related materials, Volume 2, tee on Specifications for Pharmaceutical 2nd update. Good manufacturing practices Preparations. Fortieth report. Technical Report and inspection. 2007 (388 pages) Series, No. 937. 2006 (461 pages)

2. World Health Organization. The Interna- 5. World Health Organization. International tional Pharmacopoeia, 4th edition (also nonproprietary names (INN) for pharmaceuti- available on CD-ROM). Volume 1: general cal substances. CD-ROM, 2007 (web site: notices; monographs for pharmaceutical http://bookorders.who.int/bookorders/anglais/ substances (A–O). Volume 2: monographs for qsearch1.jsp?sessla pharmaceutical substances (P–Z); monographs for dosage forms and radiopharmaceutical preparations; methods for analysis; reagents , 2006 (1499 pages)

120 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List No. 12, 2007 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement). Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM). Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

121 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

Proposed International Nonproprietary Names: List 99 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 99 Proposed INN not later than 31st of October 2008. Publication date: 1st July 2008

Dénominations communes internationales proposées: Liste 99 Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste 99 de DCI Proposées le 31 octobre 2008 au plus tard. Date de Publication: 1er Juillet 2008.

Denominaciones Comunes Internacionales Propuestas: Lista 99 Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en WHO Drug Information, es decir, para la Lista 99 de DCI Propuestas el 31 de octubre de 2008 a más tardar. Fecha de publicación: 1 de julio de 2008

Proposed INN Chemical name or description: Action and use: Molecular formula (Latin, English, French, Spanish) Chemical Abstracts Service (CAS) registry number: Graphic formula

DCI Proposée Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée

DCI Propuesta Nombre químico o descripción: Acción y uso: Fórmula molecular Número de registro del CAS: Fórmula desarrollada

acidum levomefolicum levomefolic acid N-[4-({[(6S)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin- 6-yl]methyl}amino)benzoyl]-L-glutamic acid folic acid analogue

acide lévoméfolique acide N-[4-({[(6S)-2-amino-5-méthyl-4-oxo-1,4,5,6,7,8- hexahydroptéridin-6-yl]méthyl}amino)benzoyl]-L-glutamique analogue de l'acide folique

ácido levomefólico ácido N-[4-({[(6S)-2-amino-5-metil-4-oxo-1,4,5,6,7,8- hexahydropteridin-6-il]metil}amino)benzoilo]-L-glutámico análogo del ácido fólico

C20H25N7O6 31690-09-2

O CO2HH

O CH3 N H N N N CO2H H H

H2N N N H H

122 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

aderbasibum aderbasib methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine- 1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate antineoplastic

aderbasib (6S,7S)-7(hydroxycarbamoyl)-6-[(4-phénylpipérazin-1-yl)carbonyl]- 5-azaspiro[2.5]octane-5-carboxylate de méthyle antinéoplasique

aderbasib (6S,7S)-6-(4-fenilpiperazina-1-carbonil)-7-(hidroxicarbamoil)- 5-azaspiro[2.5]octano-5-carboxilato de metilo antineoplásico

C21H28N4O5 791828-58-5

O O H3C O N N N H H NH O OH

adoprazinum adoprazine 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophenyl)pyridin- 3-yl]methyl}piperazine antidepressant

adoprazine 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophényl)pyridin- 3-yl]méthyl}pipérazine antidépresseur

adoprazina 1-(2,3-dihidro-1,4-benzodioxin-5-il)-4-{[5-(4-fluorofenil)piridin- 3-il]metil}piperazina antidepresivo

C24H24FN3O2 222551-17-9

O N O N N

afutuzumabum* afutuzumab immunoglobulin G1, anti-[Homo sapiens CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35)], humanized monoclonal antibody, GA101; gamma1 heavy chain (1-448) [humanized VH (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') - Homo sapiens IGKC*01 (113'-219')]; (228-228'':231-231'')- bisdisulfide dimer immunomodulator

123 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

afutuzumab immunoglobuline G1, anti-[Homo sapiens CD20 (membre 1 de la sous-famille A à 4 domaines transmembranaires, MS4A1, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)], anticorps monoclonal humanisé, GA101; chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (228-228'':231-231'')-bisdisulfure immunomodulateur

afutuzumab inmunoglobulina G1, anti-[Homo sapiens CD20 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, MS4A1, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)], anticuerpo monoclonal humanizado, GA101; cadena pesada gamma1 (1-448) [VH humanizada (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (228-228'':231-231'')-bisdisulfuro inmunomodulador

C6512H10060N1712O2020S44 949142-50-1

Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR 50 IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100 FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

Light chain / Chaîne légère / Cadena ligera DIVMTQTPLS LPVTPGEPAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ 50' LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLELP 100' YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150' VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200' VTHQGLSSPV TKSFNRGEC 219'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 23'-93' 23'''-93''' 139'-199' 139'''-199''' 146-202 146''-202'' 219'-222 219'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Ser-53 Ser-61 Asn-157 Thr-159 Asn-167 Thr-169

alipogenum tiparvovecum* alipogene tiparvovec recombinant adeno-associated virus serotype 1 (AAV1) vector expressing the S447X variant of the human lipoprotein lipase (LPL) gene gene therapy product (in lipoprotein disorders)

alipogène tiparvovec vecteur viral adéno-associé recombinant de type 1 (AAV1) exprimant le variant S447X du gène humain lipoprotéine lipase (LPL) produit de thérapie génique (dans les désordres liés aux lipoprotéines)

alipogén tiparvovec vector viral adeno-asociado recombinante de tipo 1 (AAV1) que expresa la variante S447X del gen humano de lipoproteina lipasa (LPL) producto para terapia génica (en alteraciones de las lipoproteínas)

929881-05-0

124 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

apricoxibum apricoxib 4-[2-(4-ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide selective cyclo-oxygenase inhibitor

apricoxib 4-[2-(4-éthoxyphényl)-4-méthyl-1H-pyrrol-1-yl]benzènesulfonamide inhibiteur selectif de la cyclo-oxygénase

apricoxib 4-[2-(4-etoxifenil)-4-metil-1H-pirrol-1-il]bencenosulfonamida inhibidor del acicloxigenasa

C19H20N2O3S 197904-84-0

O H3C OO S NH2

H3C

bafetinibum bafetinib N-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3- (dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide antineoplastic

bafétinib N-[3-([5,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3S)-3- (diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide antinéoplasique

bafetinib N-{3-[([5,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3S)-3- (dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida antineoplásico

C30H31F3N8O 887650-05-7

N H H N N N H3C N F3C H O N CH3 CH3 N

bederocinum bederocin 2-{[3-({[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen- 2-yl]methyl}amino)propyl]amino}quinolin-4(1H)-one antibacterial

bédérocine 2-{[3-({[4-bromo-5-(1-fluoroéthényl)-3-méthylthiophén- 2-yl]méthyl}amino)propyl]amino}quinoléin-4(1H)-one antibactérien

bederocina 2-{[3-({[4-bromo-5-(1-fluoroetenil)-3-metiltiofen- 2-il]metil}amino)propil]amino}quinolin-4(1H)-ona antibacteriano

125 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C20H21BrFN3OS 757942-43-1

Br H3C F H H H N N N S CH2

befiradolum befiradol (3-chloro-4-fluorophenyl)[4-fluoro-4-({[(5-methylpyridin- 2-yl)methyl]amino}methyl)piperidin-1-yl]methanone analgesic

béfiradol (3-chloro-4-fluorophényl)[4-fluoro-4-({[(5-méthylpyridin- 2-yl)méthyl]amino}méthyl)pipéridin-1-yl]méthanone analgésique

befiradol (3-cloro-4-fluorofenil)[4-fluoro-4-({[(5-metilpiridin- 2-il)metil]amino}metil)piperidin-1-il]metanona analgésico

C20H22ClF2N3O 208110-64-9

F F N H N N Cl CH3 O

bevasiranibum bevasiranib siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production duplex of thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')- guanylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')- uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')- uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- uridylyl-(3'→5')-guanosine and thymidylyl-(3'→5')-thymidylyl-(3'→5')- cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- guanylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')- cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')- cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenosine antineoplastic

126 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

bévasiranib petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l’endothélium vasculaire (VEGF) duplex de thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')- guanylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')- uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')- uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- uridylyl-(3'→5')-guanosine et thymidylyl-(3'→5')-thymidylyl-(3'→5')- cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- adénylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')- guanylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')- cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')- cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénosine antinéoplasique

bevasiranib ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor vascular de crecimiento endotelial (VEGF) duplex de timidilil-(3'→5')-timidilil-(3'→5')-uridilil-(3'→5')-guanilil- (3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil- (3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')- citidilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil- (3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanosina y timidilil-(3'→5')-timidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil- (3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')- guanilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')- citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-uridilil- (3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenosina antineoplásico

C401H503N153O290P40 959961-96-7

(3'-5') dT dT U.G. G ...... A G U G G U U C C G G U C G U G (5'-3') ACC U C A C C A A G G C C A G C A C dT dT

catridecacogum* catridecacog human Factor XIII [A2] homodimer (allele F13A*1B), recombinant DNA origin blood coagulation factor

catridécacog chaîne A du facteur XIII de coagulation humain non-activée (allèle F13A*1B), homodimère, origine ADN recombinant facteur de coagulation sanguine

catridecacog cadena A del factor XIII de coagulación humano no activado (alelo F13A*1B), homodímero, origen ADN recombinante factor de coagulación sanguínea

127 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C3708H5735N1013O1111S28 606138-08-3

SETSRTAFGG RRAVPPNNSN AAEDDLPTVE LQGVVPRGVN LQEFLNVTSV 50 HLFKERWDTN KVDHHTDKYE NNKLIVRRGQ SFYVQIDFSR PYDPRRDLFR 100 VEYVIGRYPQ ENKGTYIPVP IVSELQSGKW GAKIVMREDR SVRLSIQSSP 150 KCIVGKFRMY VAVWTPYGVL RTSRNPETDT YILFNPWCED DAVYLDNEKE 200 REEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCLY VMDRAQMDLS 250 GRGNPIKVSR VGSAMVNAKD DEGVLVGSWD NIYAYGVPPS AWTGSVDILL 300 EYRSSENPVR YGQCWVFAGV FNTFLRCLGI PARIVTNYFS AHDNDANLQM 350 DIFLEEDGNV NSKLTKDSVW NYHCWNEAWM TRPDLPVGFG GWQAVDSTPQ 400 ENSDGMYRCG PASVQAIKHG HVCFQFDAPF VFAEVNSDLI YITAKKDGTH 450 VVENVDATHI GKLIVTKQIG GDGMMDITDT YKFQEGQEEE RLALETALMY 500 GAKKPLNTEG VMKSRSNVDM DFEVENAVLG KDFKLSITFR NNSHNRYTIT 550 AYLSANITFY TGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLE 600 QASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQ VVGSDMTVTV 650 EFTNPLKETL RNVWVHLDGP GVTRPMKKMF REIRPNSTVQ WEEVCRPWVS 700 GHRKLIASMS SDSLRHVYGE LDVQIQRRPS M 731 Modified residues / Résidus modifiés / Residuos modificados OH S O H 1 N-acetylSer H3C N CO2H H

citatuzumabum bogatoxum* citatuzumab bogatox immunoglobulin Fab fusion protein, anti-[Homo sapiens tumor- associated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP- 2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, CD326)], humanized Fab fused with Bougainvillea spectabilis Willd rRNA N-glycosidase [type I ribosome inactivating protein (RIP), bouganin], VB6-845; gamma1 heavy chain fragment (1-225) [hexahistidyl (1-6) -humanized VH from 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1-hinge fragment EPKSC (123-225)], (225-219')-disulfide with kappa fusion chain (1'-481') [humanized V-KAPPA from clone 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer furin linker (proteolytic cleavage spacer from Pseudomonas exotoxin A) (220'-231') -Bougainvillea spectabilis Willd bouganin fragment (27-276 from precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')] antineoplastic

citatuzumab bogatox immunoglobuline Fab protéine de fusion, anti-[Homo sapiens transducteur 1 du signal calcium associé aux tumeurs (TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, molécule d’adhésion de la cellule épithéliale Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, CD326)], humanisé Fab fusionné avec la N-glycosidase de l’ARNr [protéine de type I inactivant le ribosome (RIP), bouganine] de Bougainvillea spectabilis Willd, VB6-845; fragment de chaîne lourde gamma1 (1-225) [hexahistidyl (1-6) -VH humanisé de 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1- fragment de la charnière EPKSC (123-225)], (225-219')-disulfure avec la chaîne kappa de fusion (1'-481') [V-KAPPA humanisé du clone 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer furin linker (motif de clivage protéolytique de Pseudomonas exotoxin A) (220'-231') - Bougainvillea spectabilis Willd bouganine fragment (27-276 du précurseur, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')] antinéoplasique

128 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

citatuzumab bogatox inmunoglobulina Fab proteina de fusión, anti-[Homo sapiens transductor 1 de la señal de calcio asociado a tumores (TACSTD1, proteina 2 asociada a tumores gastrointestinales, GA733-2, glicoproteíne epitelial 2, EGP-2, molécula de adhesión de la célula epitelial Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, CD326)], humanizado Fab fusionado con la N-glicosidasa de ARNr [proteína de tipo I inactivadora del ribosoma (RIP), buganina] de Bougainvillea spectabilis Willd, VB6-845; fragmento de cadena pesada gamma1 (1-225) [hexahistidil (1-6) -VH humanizado de 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1- fragmento de la bisagra EPKSC (123-225)], (225-219')-disulfuro con la cadena kappa de fusión (1'-481') [V-KAPPA humanizado del clon 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer ligante de furina (espaciador de ruptura proteolítica de Pseudomonas exotoxin A) (220'-231') – buganina de Bougainvillea spectabilis Willd fragmento (27-276 del precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')] antineoplásico

C3455H5371N921O1060S18 945228-49-9

Heavy chain / Chaîne lourde / Cadena pesada HHHHHHEVQL VQSGPGLVQP GGSVRISCAA SGYTFTNYGM NWVKQAPGKG 50 LEWMGWINTY TGESTYADSF KGRFTFSLDT SASAAYLQIN SLRAEDTAVY 100 YCARFAIKGD YWGQGTLLTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200 QTYICNVNHK PSNTKVDKKV EPKSC 225 Light chain-toxin / Chaîne légère-toxine / Cadena ligera-toxina DIQMTQSPSS LSASVGDRVT ITCRSTKSLL HSNGITYLYW YQQKPGKAPK 50' LLIYQMSNLA SGVPSRFSSS GSGTDFTLTI SSLQPEDFAT YYCAQNLEIP 100' RTFGQGTKVE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150' VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200' VTHQGLSSPV TKSFNRGECT RHRQPRGWEQ LYNTVSFNLG EAYEYPTFIQ 250' DLRNELAKGT PVCQLPVTLQ TIADDKRFVL VDITTTSKKT VKVAIDVTDV 300' YVVGYQDKWD GKDRAVFLDK VPTVATSKLF PGVTNRVTLT FDGSYQKLVN 350' AAKADRKALE LGVNKLEFSI EAIHGKTING QEAAKFFLIV IQMVSEAARF 400' KYIETEVVDR GLYGSFKPNF KVLNLENNWG DISDAIHKSS PQCTTINPAL 450' QLISPSNDPW VVNKVSQISP DMGILKFKSS K 481' Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 23'-93' 28-102 139'-199' 149-205 219'-225 263'-443'

conatumumabum* conatumumab immunoglobulin G1, anti-[Homo sapiens tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, TR-2, CD262)], Homo sapiens monoclonal antibody, XG1-048 v w (or AMG 655, TRAIL-R2mAb); gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) - IGHG1*03 (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (231-231'':234-234'')-bisdisulfide dimer antineoplastic

129 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

conatumumab immunoglobuline G1, anti-[Homo sapiens membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFRSF10B, death receptor 5, DR5, TRAIL-R2, TR-2, CD262)], Homo sapiens anticorps monoclonal, XG1-048 v w (ou AMG 655, TRAIL-R2mAb); chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') - IGKC*01 (109'-215')]; dimère (231-231'':234-234'')-bisdisulfure antinéoplasique

conatumumab inmunoglobulina G1, anti-[Homo sapiens miembro 10B de la superfamilia de receptores del factor de necrosis tumoral (TNFRSF10B, receptor mortal 5, DR5, TRAIL-R2, TR-2, CD262)], Homo sapiens anticorps monoclonal, XG1-048 v w (o AMG 655, TRAIL-R2mAb); cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') - IGKC*01 (109'-215')]; dímero (231-231'':234-234'')-bisdisulfuro antineoplásico

C6466H10006N1730O2024S40 896731-82-1

Heavy γ1-chain / Chaîne lourde γ1 / Cadena pesada γ1 QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYFWSWIR QLPGKGLEWI 50 GHIHNSGTTY YNPSLKSRVT ISVDTSKKQF SLRLSSVTAA DTAVYYCARD 100 RGGDYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200 QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400 PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450 GK 452 Light κ-chain / Chaîne légère κ / Cadena ligera κ EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK PGQAPSLLIY 50' GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QFGSSPWTFG 100' QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150' VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200' GLSSPVTKSF NRGEC 215' Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-97 22''-97'' 23'-89' 23'''-89''' 135'-195' 135'''-195''' 149-205 149''-205'' 215'-225 215'''-225'' 231-231'' 234-234'' 266-326 266''-326'' 372-430 372''-430''

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N = Asn-302 Asn-302''

custirsenum custirsen 2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O- (2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)- P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy- P-thioadenylyl-(3'→5')-2'-deoxy-(3'→5')-2'-deoxy-P-thioguanylyl- (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl- (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)- P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine antineoplastic

130 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

custirsen 2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O- (2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl- P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy- P-thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy- P-thioadénylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy- P-thioadénylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy- P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-O-(2- méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- 5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl- P-thiouridine antinéoplasique

custirsén 2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)- P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O- (2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil- (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')- 2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-(3'→5')-2'-desoxi-P- tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P- tioguanilil-(3'→5')- P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil- (3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi- P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridll- (3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O -(2- metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina antineoplásico

C231H312N78O119P20S20 903916-27-8

(3' 5')d(P-thio)(rC-rA-rG-rC-A-G-C-A-G-A-G-T-C-T-T-C-A-rU-rC-rA-rU) Modified nucleosides A = 2'-O-(2-methoxyethyl)adenosine C = 2'-O-(2-methoxyethyl)-5-methylcytidine G = 2'-O-(2-methoxyethyl)guanosine U = 2'-O-(2-methoxyethyl)-5-methyluridine

danusertibum danusertib N-{5-[(2R)-2-methoxy-2-phenylacetyl]-1,4,5,6-tetrahydropyrrolo= [3,4-c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide antineoplastic

danusertib N-{5-[(2R)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo= [3,4-c]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide antinéoplasique

danusertib N-{5-[(2R)-2-fenil-2-metoxiacetil]-1,4,5,6-tetrahidropirrolo= [3,4-c]pirazol-3-il}-4-(4-metilpiperazin-1-il)benzamida antineoplásico

131 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C26H30N6O3 827318-97-8

N N H OCH3 N HN N H3C O

darotropii bromidum darotropium bromide (1R,3r,5S)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl- 8-azabicyclo[3.2.1]octan-8-ium bromide anticholinergic

bromure de darotropium bromure de (1R,3r,5S)-3-(2-cyano-2,2-diphényléthyl)-8,8-diméthyl- 8-azabicyclo[3.2.1]octan-8-ium anticholinergique

bromuro de darotropio bromuro de (1R,3r,5S)-3-(2-ciano-2,2-difeniletil)-8,8-dimetil- 8-azabiciclo[3.2.1]octan-8-io anticolinérgico

C24H29BrN2 850607-58-8

H CH3 N+ Br CH3 NC H

demiditrazum demiditraz 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole acaricide (veterinary use)

démiditraz 2-[(1S)-1-(2,3-diméthylphényl)éthyl]-1H-imidazole acaricide (usage vétérinaire)

demiditraz 2-[(1S)-1-(2,3-dimetilfenil)etil]-1H-imidazol acaricida (veterinario)

C13H16N2 944263-65-4

CH 3 H CH3 H3C N

denenicokinum denenicokin recombinant L-methionyl(human interleukin-21) (134 amino acids), produced in Escherichia coli immunomodulator

132 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

dénénicokine L-méthionyl(interleukine-21 humaine), recombinante (134 acides aminés), produite par Escherichia coli immunomodulateur

denenicokina L l-metionil(interleukina-21 humana), recombinante (134 aminoácido, producida por Escherichia coli inmunomodulador

C676H1087N205O203S8 716840-32-3

M QGQDRHMIRM RQLIDIVDQL KNYVNDLVPE FLPAPEDVET NCEWSAFSCF 50 QKAQLKSANT GNNERIINVS IKKLKRKPPS TNAGRRQKHR LTCPSCDSYE 100 KKPPKEFLER FKSLLQKMIH QHLSSRTHGS EDS 133

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 42-93 49-96

derquantelum derquantel (1'R,5a'S,7'R,8a'S,9a'R)-1'-hydroxy-1',4,4,8',8',11'-hexamethyl- 2',3',8a',9,9',10-hexahydro-4H,1'H,5'H,6'H,8'H- spiro[[1,4]dioxepino[2,3-g]indole-8,7'- [5a,9a](epiminomethano)cyclopenta[f]indolizin]-10'-one anthelmintic

derquantel (1'R,5'aS,7'R,8'aS,9'aR)-1'-hydroxy-1',4,4,8',8',11'-hexaméthyl- 2',3',8'a,9,9',10-hexahydro-1'H,4H,5'H,6'H,8'H- spiro[[1,4]dioxépino[2,3-g]indole-8,7'- [5a,9a](épiminométhano)cyclopenta[f]indolizin]-10'-one anthelmintique

derquantel (1'R,5a'S,7'R,8a'S,9a'R)-1'-hidroxi-1',4,4,8',8',11'-hexametil- 2',3',8a',9,9',10-hexahidro-4H,1'H,5'H,6'H,8'H- espiro[[1,4]dioxepino[2,3-g]indol-8,7'- [5a,9a](epiminometano)ciclopenta[f]indolizin]-10'-ona antihelmíntico

C28H37N3O4 187865-22-1

H3C NH N O H O N

H3C CH 3 O CH3 CH3 OH CH3

disitertidum disitertide human transforming growth factor-beta receptor type III-(710-723)- peptide transforming growth factor beta-1 inhibitor

disitertide récepteur de type III du facteur de croissance transformant-bêta humain-(710-723)-peptide inhibiteur du facteur de croissance transformant bêta-1

disitertida receptor de tipo III del factor de crecimiento transformador-beta humano-(710-723)-péptido factor de crecimiento transformador beta-1 inhibidor

133 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C68H109N17O22S2 272105-42-7

HThr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln Asn OH 10 14

drinabantum drinabant N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- N-(3,5-difluorophenyl)methanesulfonamide cannabinoid receptor antagonist

drinabant N-{1-[bis(4-chlorophényl)méthyl]azétidin-3-yl}- N-(3,5-difluorophényl)méthanesulfonamide antagoniste des récepteurs aux cannabinoïdes

drinabant N-{1-[bis(4-clorofenil)metil]azetidin-3-il}- N-(3,5-difluorofenil)metanosulfonamida antagonista del receptor de cannabinoides

C23H20Cl2F2N2O2S 358970-97-5

O CH3 O S Cl N F

dulanerminum dulanermin human tumor necrosis factor ligand superfamily member 10 (TNF- related apoptosis-inducing ligand or Apo-2 ligand or CD253 antigen)- (114-281)-peptide (C-terminal part of the extracellular domain), noncovalent homotrimer antineoplastic

dulanermine membre 10 de la superfamille de ligand du facteur de nécrose tumorale humain (ligand inducteur d’apoptose apparenté au TNF ou Apo-2 ligand ou antigène CD253)-(114-281)-peptide (extrémité C-terminale du domaine extracellulaire), homotrimère nonacovalent antinéoplasique

dulanermina miembro 10 de la superfamilia de ligandos del factor de necrosis tumoral humano (ligando inductor de apoptosis relacionada con el TNF o Apo-2 ligand o antígeno CD253)-(114-281)-péptido (extremo C-terminal del dominio extracelular), homotrímero nonacovalente antineoplásico

C871H1329N243O260S4 867153-61-5

Monomer VRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF 50 LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY 100 TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE 150 HLIDMDHEAS FFGAFLVG 168

134 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

edoxabanum edoxaban N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)- 2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine- 2-carboxamido)cyclohexyl]oxamide antithrombotic

édoxaban N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-diméthylcarbamoyl)- 2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-c]pyridine- 2-carboxamido)cyclohexyl]oxamide antithrombotique

edoxabán N-(5-cloropiridin-2-il)-N'-[(1S,2R,4S)-4-(N,N-dimetilcarbamoil)- 2-(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridina- 2-carboxamido)ciclohexil]oxamida antitrombótico

C24H30ClN7O4S 480449-70-5

O CH3 H N

CH3 O H N Cl N O H H S HN N N N H O H3C

elagolixum elagolix 4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro- 6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl}amino)butanoic acid GnRH antagonist

élagolix acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-{[2-fluoro- 6-(trifluorométhyl)phényl]méthyl}-4-méthyl-2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phényléthyl}amino)butanoïque antagonist de la GnRH

elagolix ácido 4-({(1R)-2-[5-(2-fluoro-3-metoxifenil)-3-{[2-fluoro- 6-(trifluorometil)fenil]metil}-4-metil-2,6-dioxo-3,6-dihidropirimidin- 1(2H)-il)-1-feniletil}amino)butanoico antagonista de GnRH

C32H30F5N3O5 834153-87-6

O H N CO2H H3CO N F H H3C N O F

F3C

135 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

elesclomolum elesclomol N,N'-dimethyl-N,N'-di(benzenecarbonothioyl)propanedihydrazide antineoplastic (adjunctive agent)

élesclomol 1-N',3-N'-diméthyl-1-N',3-N'- dibenzènecarbonothioylpropanedihydrazide antinéoplasique (adjuvant)

elesclomol N,N'-dimetil-N,N'-di(bencenocarbonotioil)propanodihidrazida antineoplásico (coadyuvante)

C19H20N4O2S2 488832-69-5

CH3 O O CH3 N N N N H H S S

entinostatum entinostat (pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}= methyl)carbamate antineoplastic

entinostat ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate de pyridin- 3-ylméthyle antinéoplasique

entinostat ({4-[(2-aminofenil)carbamoil]fenil}metil)carbamato de (piridin- 3-il)metilo antineoplásico

C21H20N4O3 209783-80-2

N H H NH2 N O N

eprotiromum eprotirome 3-({3,5-dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}amino)- 3-oxopropanoic acid antihyperlipidaemic

éprotirome acide 3-({3,5-dibromo-4-[4-hydroxy-3-(1-méthyléthyl)phénoxy]= phényl}amino)-3-oxopropanoïque antihyperlipidémiant

eprotiromo ácido 3-({3,5-dibromo-4-[4-hidroxi-3-(propan-2-il)fenoxi]fenil}amino)- 3-oxopropanoico antihiperlipémico

136 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

C18H17Br2NO5 355129-15-6

H HO Br N CO2H

H3C O O

CH3 Br

esreboxetinum esreboxetine (2S)-2-[(2-ethoxyphenoxy)(phenyl)methyl]morpholine antidepressant

esréboxétine (+)-(2S)-2-[(S)-(2-éthoxyphénoxy)phénylméthyl]morpholine antidépresseur

esreboxetina (2S)-2-[(2-etoxifenoxi)(fenil)metil]morfolina antidepresivo

C19H23NO3 98819-76-2

H H O ONH H3C O

etaracizumabum* etaracizumab immunoglobulin G1, anti-[Homo sapiens alphaVbeta3 integrin (CD51/CD61, CD51/GPIIIa, CD51/platelet membrane glycoprotein IIIa, vitronectin receptor)], humanized monoclonal antibody, MEDI- 522 (or hLM609); gamma1 heavy chain (1-447) [humanized VH (Homo sapiens FR/Mus musculus CDR from clone LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR from clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (108'-214')]; (226-226”:230-230”)- bisdisulfide dimer antineoplastic

étaracizumab immunoglobuline G1, anti-[Homo sapiens alphaVbeta3 intégrine (CD51/CD61, CD51/GPIIIa, CD51/glycoprotéine membranaire IIIa des plaquettes, récepteur de la vitronectine)], anticorps monoclonal humanisé, MEDI-522 (ou hLM609); chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens FR/Mus musculus CDR du clone LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR du clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (226-226”:230-230”)-bisdisulfure antinéoplasique

137 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

etaracizumab inmunoglobulina G1, anti-[Homo sapiens alfaVbeta3 integrina (CD51/CD61, CD51/GPIIIa, CD51/glicoproteina IIIa de membrana de plaquetas, receptor de la vitronectina)], anticuerpo monoclonal humanizado, MEDI-522 (o hLM609); cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens FR/Mus musculus CDR del clon LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) - Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens FR/Mus musculus CDR del clon LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (226-226”:230-230”)-bisdisulfuro antineoplásico

C6392H9908N1732O1996S42 892553-42-3

γ−Heavy chain/ Chaîne γ lourde / Cadena γ pesada QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYDMSWVRQA PGKGLEWVAK 50 VSSGGGSTYY LDTVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARHL 100 HGSFASWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

κ−Light chain / Chaîne κ légère/ Cadena κ ligera EIVLTQSPAT LSLSPGERAT LSCQASQSIS NFLHWYQQRP GQAPRLLIRY 50' RSQSISGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SGSWPLTFGG 100' GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150' DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200' LSSPVTKSFN RGEC 214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22''-96'' 23'-88' 23'''-88''' 134'-194' 134'''-194''' 144-200 144''-200''

214'-220 214'''-220'' 226-226'' 229-229'' 261-321 261''-321'' 367-425 367''-425''

foravirumabum* foravirumab immunoglobulin G1, anti-[rabies virus glycoprotein], Homo sapiens monoclonal antibody, CR4098; gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-33-(IGHD)-IGHJ4*01) [8.8.12] (1-119) - IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-17- IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228'':231- 231'')-bisdisulfide dimer antiviral (rabies prophylaxy)

foravirumab immunoglobuline G1, anti-[glycoprotéine du virus de la rage], Homo sapiens anticorps monoclonal, CR4098; chaîne lourde gamma1 (1-448) [Homo sapiens VH (IGHV3-33-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17-IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure antiviral (prophylaxie de la rage)

138 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

foravirumab inmunoglobulina G1, anti-[glicoproteína del virus de la rabia], Homo sapiens anticuerpo monoclonal, CR4098; cadena pesada gamma1 (1-448) [Homo sapiens VH (IGHV3-33-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17-IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro antiviral (profilaxis de la rabia)

C6400H9908N1716O1998S44 944548-38-3

Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG AVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50 ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVA 100 VAGTHFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKLLIYA 50' ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LNSYPPTFGG 100' GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150' DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200' LSSPVTKSFN RGEC 214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 23'-88' 23'''-88''' 134'-194' 134'''-194''' 146-202 146''-202'' 214'-222 214'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''

Modified residues / Résidus modifiés / Residuos modificados

E H pyroglutamic acid 1-1'-1''-1''' acide pyroglutamique CO H N 2 acido piroglutamico O H

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-299 Asn-299''

ibipinabantum ibipinabant (E,4S)-N′-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-N-methyl- 4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide cannabinoid receptor antagonist

ibipinabant (E,4S)-N′-(4-chlorobenzènesulfonyl)-3-(4-chlorophényl)-N-méthyl- 4-phényl-4,5-dihydro-1H-pyrazole-1-carboximidamide antagoniste des récepteurs cannabinoïdes

ibipinabant (E,4S)-N′-(4-clorobencenosulfonil)-3-(4-clorofenil)-4-fenil-N-metil- 4,5-dihidro-1H-pirazol-1-carboximidamida antagonista del receptor de cannabinoides

C23H20Cl2N4O2S 464213-10-3

H3C NH OO S N N H N Cl

139 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

inolitazonum inolitazone rac-5-[(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl- 1H-benzimidazol-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine- 2,4-dione antineoplastic

inolitazone rac-5-[(4-{[6-(4-amino-3,5-diméthylphénoxy)-1-méthyl- 1H-benzimidazol-2-yl]méthoxy}phényl)méthyl]thiazolidine-2,4-dione antinéoplasique

inolitazona rac-5-[(4-{[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1H-benzoimidazol- 2-il]metoxi}fenil)metil]-1,3-tiazolidina-2,4-diona antineoplásico

C27H26N4O4S 223132-37-4

H3C

H2N O

CH3 and enantiomer H C 3 N O et énantiomère y enantiómero O N S NH

H O

lancovutidum 3,15 3,15 lancovutide (C R)-C -hydroxy[2-L-lysine,10-L-phenylalanine, 12-L-phenylalanine-,13-L-valine]lantibiotic ancovenin (Streptomyces sp) expectorant (in cystic fibrosis)

3,15 3,15 lancovutide (C R)-C -hydroxy[2-L-lysine,10-L-phénylalanine, 12-L-phénylalanine-,13-L-valine]ancovénine antibiotique (Streptomyces sp) expectorant (dans la fibrose kystique)

3,15 3,15 lancovutida C R)-C -hidroxi[2-L-lisina,10-L-fenilalanina, 12-L-fenilalanina-,13-L-valina]ancovenina antibiótico (Streptomyces sp) expectorante (en fibrosis quística)

C89H125N23O25S3 1391-36-2

CH3 S S CH HO C 3 2 OH H H H S H H H H O H H H H2N Lys Gln N N N Phe Gly Pro Phe N Phe Val N N Gly Asn N N CO2H H H H H H H O O O O O O O H H HN

140 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

larazotidum larazotide glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine zonulin antagonist (in celiac disease)

larazotide glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine antagoniste de la zonuline (dans la maladie cœliaque)

larazotida glicilglicil-L-valil-L-leucil-L-valil-L-glutaminil-L-prolilglicina antagonista de la zonulina (en la enfermedad celíaca)

C32H55N9O10 258818-34-7

HGly Gly Val Leu Val Gln Pro Gly OH

lensiprazinum lensiprazine (2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperidin-1-yl}-2-methyl- 2H-1,4-benzoxazin-3(4H)-one antidepressant

lensiprazine (-)-(2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]pipérazin-1-yl}- 2-méthyl-2H-1,4-benzoxazin-3(4H)-one antidépresseur

lensiprazina (2R)-8-{4-[3-(5-fluoro-1H-indol-3-il)propil]piperidin-1-il}-2-metil- 2H-1,4-benzoxazin-3(4H)-ona antidepresivo

C24H27FN4O2 327026-93-7

HN N NH O N O HCH3

levomilnacipranum levomilnacipran (1S,2R)-2-(aminomethyl)-N,N-diethyl- 1-phenylcyclopropanecarboxamide antidepressant

lévomilnacipran (-)-(1S,2R)-2-(aminométhyl)-N,N-diéthyl- 1-phénylcyclopropanecarboxamide antidépresseur

levomilnaciprán (-)-(1S,2R)-2-(aminometil)-N,N-dietil-1-fenilciclopropanocarboxamida antidepresivo

C15H22N2O 96847-55-1

CH3

O N CH3 H

NH2

141 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

linagliptinum linagliptin 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl- 1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione antidiabetic

linagliptine 8-[(3R)-3-aminopipéridin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl- 1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1H-purine-2,6-dione antidiabétique

linagliptina 8-[(3R)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil- 1-[(4-metilquinazolin-2-il)metil]-3,7-dihidro-1H-purina-2,6-diona hipoglucemiante

C25H28N8O2 668270-12-0

CH3 O H NH2 N N N N N O N N CH3 CH3

lixisenatidum lixisenatide des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)- peptidylpenta-L-lysyl-L-lysinamide antidiabetic

lixisénatide dés-38-proline-exendine-4 (Heloderma suspectum)-(1-39)- peptidylpenta-L-lysyl-L-lysinamide antidiabétique

lixisenatida des-38-prolina-exendina-4 (Heloderma suspectum)-(1-39)- peptidilpenta-L-lisil-L-lisinamida hipoglucemiante

C215H347N61O65S 320367-13-3

HHis Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met 10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20 Gly Gly Pro Ser Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys 30 40

Lys Lys NH2 44

macitentanum macitentan N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxi]ethoxy}= pyrimidin-4-yl]-N'-propylsulfuric diamide endothelin receptor antagonist

macitentan N-[5-(4-bromophényl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]éthoxy}= pyrimidin-4-yl]-N'-propyldiamide sulfurique antagoniste du récepteur de l'endothéline

macitentan N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimidin- 4-il]-N'-propildiamida sulfúrica antagonista del receptor de endotelina

142 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

C19H20Br2N6O4S 441798-33-0

H3C S Br N NH H N O N N O N Br

melogliptinum melogliptin (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-1-yl)methyl]= cyclopentyl}amino)acetyl]pyrrolidine-2-carbonitrile antidiabetic

mélogliptine (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-1-yl)méthyl]= cyclopentyl}amino)acétyl]pyrrolidine-2-carbonitrile antidiabétique

melogliptina (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-1-il)metil]= ciclopentil}amino)acetil]pirrolidina-2-carbonitrilo hipoglucemiante

C15H21FN6O 868771-57-7

O H H CN N N N N H H N F H

mimopezilum mimopezil (5R,9R)-5-{[(5-chloro-2-hydroxy-3-methoxyphenyl)methylidene]= amino}-11-[(E)-ethylidene]-7-methyl-5,6,9,10-tetrahydro- 5,9-methanocycloocta[b]pyridin-2(1H)-one acetyl cholinesterase inhibitor

mimopézil (5R,9R)-5-{[(5-chloro-2-hydroxy-3-méthoxyphényl)= méthylidène]amino}-11-[(E)-ethylidène]-7-méthyl-5,6,9,10- tétrahydro-5,9-méthanocycloocta[b]pyridin-2(1H)-one inhibiteur de l'acétylcholine estérase

mimopezil (5R,9R)-5-{[(5-cloro-2-hidroxi-3-metoxifenil)metilideno]amino}- 11-[(E)-etilideno]-7-metil-5,6,9,10-tetrahidro- 5,9-metanocicloocta[b]piridin-2(1H)-ona inhibidor de la acetilcolinesterasa

143 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C23H23ClN2O3 180694-97-7

H H N O

H3C

H3C N OH

OCH3

mipomersenum mipomersen antisense oligonucleotide inhibitor of apolipoprotein B (APOB) expression 2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl- P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl- (3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'- deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy- 5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O- (2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)- 5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)- P-thioadenylyl-(3' →5')-2'-O-(2-methoxyethyl)-5-methyl- P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine antihypercholesterol agent

mipomersen oligonucléotide antisens, inhibiteur de l’expression de l’apolipoprotéine B (APOB) 2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- 5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl- P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl- (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'- déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy- 5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P- thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O- (2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- 5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)- P-thioadénylyl-(3'→ 5')-2'-O-(2-méthoxyéthyl)-5-méthyl- P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidine antihypercholestérolémique

144 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

mipomersen oligonucleótido antisentido inhibidor de la expresión de la apolipoproteina B (APOB) 2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil- P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'- O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)- 5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi- P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil- P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil- (3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-P- tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-O- (2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil- P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O- (2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)- 5-metilcitidina antihipercolesterolémico

C230H324N67O122P19S19 1000120-98-8

(3'-5')(P-thio)(G-C-C-U-C-dA-dG-dT-dC-dT-dG-dC-dT-dT-dC-G-C-A-C-C)

Modified nucleosides / Nucléosides modifiés / Nucleósidos modificados

A N C : R = O-CH2-CH2-OCH3 N NH 2 dC : R = H OH O O N NH2 NN OH O N OCH3 CH3 HO O

G H2N HO R NH U N O H O N O OH OH O NN O N CH3

OCH3 OCH3 HO O HO O

olesoximum olesoxime (EZ)-N-(cholest-4-en-3-ylidene)hydroxylamine neurodegenerative disorders

olésoxime (EZ)-N-(cholest-4-én-3-ylidène)hydroxylamine maladies neurodegeneratives

olesoxima (EZ)-N-(colest-4-en-3-ilideno)hidroxilamina enfermedades neurodegenerativas

C27H45NO 22033-87-0

H H3C CH 3 CH H 3

CH3 H H3C

H H N HO

145 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

ombrabulinum ombrabulin (2S)-2-amino-3-hydroxy-N-{2-methoxy- 5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl}propanamide antineoplastic

ombrabuline (2S)-2-amino-3-hydroxy-N-{2-méthoxy- 5-[(1Z)-2-(3,4,5-triméthoxyphényl)éthényl]phényl]propanamide antinéoplasique

ombrabulina (2S)-2-amino-3-hidroxi-N-{2-metoxi- 5-[(1Z)-2-(3,4,5-trimetoxifenil)etenil]fenil}propanamida antineoplásico

C21H26N2O6 181816-48-8

H3CO

H3CO O

OCH3 N OH H HNH OCH3 2

otenabantum otenabant 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- 4-(ethylamino)piperidine-4-carboxamide cannabinoid receptor antagonist

oténabant 1-[8-(2-chlorophényl)-9-(4-chlorophényl)-9H-purin-6-yl]- 4-(éthylamino)pipéridine-4-carboxamide antagoniste des récepteurs cannabinoïdes

otenabant 1-[8-(2-clorofenil)-9-(4-clorofenil)-9H-purin-6-il]- 4-(etilamino)piperidina-4-carboxamida antagonista del receptor de cannabinoides

C25H25Cl2N7O 686344-29-6

NN Cl N N O N

NH NH2 Cl CH3

palifosfamidum palifosfamide N,N'-bis(2-chloroethyl)phosphorodiamidic acid antineoplastic

palifosfamide acide N,N'-bis(2-chloroéthyl)phosphorodiamidique antinéoplasique

palifosfamida ácido N,N'-bis(2-cloroetil)fosforodiamídico antineoplásico

146 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

C4H11Cl2N2O2P 31645-39-3

Cl HN O P HO HN Cl

palovarotenum palovarotene 4-[(1E)-2-{5,5,8,8-tetramethyl-3-[(1H-pyrazol-1-yl)methyl]- 5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl]benzoic acid retinoid acid receptor agonist

palovarotène acide 4-{(1E)-2-[5,5,8,8-tétraméthyl-3-(1H-pyrazol-1-ylméthyl)- 5,6,7,8-tétrahydronaphtalén-2-yl]éthényl}benzoïque agoniste du récepteur de l'acide rétinoïque

palovarotena ácido 4-[(1E)-2-{5,5,8,8-tetrametil-3-[(1H-pirazol-1-il)metil]- 5,6,7,8-tetrahidronaftalen-2-il}etenil]benzoico agonista del receptor de ácido retinoico

C27H30N2O2 410528-02-8

CO2H H3C CH3

H3CCH3 N N

radezolidum radezolid N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol-4-yl]methyl)amino]= methyl}[1,1'-biphenyl]-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}= acetamide antibacterial

radézolid N-{[(5S)-3-(2-fluoro-4'-{[(1H-1,2,3-triazol-4-ylméthyl)amino]= méthyl}biphényl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]méthyl}acétamide antibactérien

radezolid N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol-4-il]metil)amino]metil}= [1,1'-bifenil]-4-il)-2-oxo-1,3-oxazolidin-5-il]metil}acetamida antibacteriano

C22H23FN6O3 869884-78-6

O O H H H3C N N

O H N H N F N N

147 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

rafivirumabum* rafivirumab immunoglobulin G1, anti-[rabies virus glycoprotein], Homo sapiens monoclonal antibody, CR57; gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV1-69-(IGHD)-IGHJ5*02) [8.8.20] (1-127) - IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfide with lambda light chain (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11- IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; (236-236'':239- 239'')-bisdisulfide dimer antiviral (rabies prophylaxy)

rafivirumab immunoglobuline G1, anti-[glycoprotéine du virus de la rage], Homo sapiens anticorps monoclonal, CR57; chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV1-69-(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfure avec la chaîne légère lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11-IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dimère (236-236'':239-239'')-bisdisulfure antiviral (prophylaxie de la rage)

rafivirumab inmunoglobulina G1, anti-[glicoproteína del virus de la rabia], Homo sapiens anticuerpo monoclonal, CR57; cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV1-69-(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfuro con la cadena ligera lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11-IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dímero (236-236'':239-239'')-bisdisulfuro antiviral (profilaxis de la rabia)

C6462H9942N1714O2036S46 944548-37-2

Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGAE VKKPGSSVKV SCKASGGTFN RYTVNWVRQA PGQGLEWMGG 50 IIPIFGTANY AQRFQGRLTI TADESTSTAY MELSSLRSDD TAVYFCAREN 100 LDNSGTYYYF SGWFDPWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200 SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250 FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350 GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400 YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450 LSLSPG 456

Light chain / Chaîne légère / Cadena ligera ESALTQPRSV SGSPGQSVTI SCTGTSSDIG GYNFVSWYQQ HPGKAPKLMI 50' YDATKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC CSYAGDYTPG 100' VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150' TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200' VTHEGSTVEK TVAPTECS 218'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 22'-90' 22'''-90''' 140'-199' 140'''-199''' 154-210 154''-210'' 217'-230 217'''-230'' 236-236'' 239-239'' 271-331 271''-331'' 377-435 377''-435''

Modified residues / Résidus modifiés / Residuos modificados

E H pyroglutamic acid 1-1'-1''-1''' acide pyroglutamique CO H N 2 acido piroglutamico O H

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-307 Asn-307''

retaspimycinum retaspimycin (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy- 8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en- 1-yl)amino]-2-azabicyclo[16.3.1]docasa-1(21)4,6,10,18(22),19- hexaen-9-yl carbamate antineoplastic

148 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

rétaspimycine carbamate de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22- trihydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3-oxo-19-(prop- 2-énylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19- hexén-9-yle antinéoplasique

retaspimicina carbamato de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22- trihidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3-oxo-19-[(prop-2-en- 1-il)amino]-2-azabiciclo[16.3.1]docasa-1(21)4,6,10,18(22),19- hexaen-9-ilo antineoplásico

C31H45N3O8 857402-23-4

CH3 O H HO NH O NH2 H3CO H H2C H3C O N OH H H OH

H H H CH CH 3 OCH3 3

saracatinibum saracatinib N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin- 1-yl)ethoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine antineoplastic

saracatinib N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-méthylpipérazin- 1-yl)éthoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine antinéoplasique

saracatinib N-(5-cloro-1,3-benzodioxol-4-il)-7-[2-(4-metilpiperazin-1-il)etoxi]- 5-[(oxan-4-il)oxi]quinazolin-4-amina antineoplásico

C27H32ClN5O5 379231-04-6

O N N N N H3C Cl O HN

O O O

semagacestatum semagacestat (2S)-2-hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo- 2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan- 2-yl]butanamide gamma secretase inhibitor

149 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

sémagacestat (2S)-2-hydroxy-3-méthyl-N-[(2S)-1-{[(1S)-3-méthyl-2-oxo- 2,3,4,5-tétrahydro-1H-3-benzazépin-1-yl]amino}-1-oxopropan- 2-yl]butanamide inhibiteur de la secrétase gamma

semagacestat (2S)-2-hidroxi-3-metil-N-[(2S)-1-{[(1S)-3-metil-2-oxo- 2,3,4,5-tetrahidro-1H-3-benzazepin-1-il]amino}-1-oxopropan- 2-il]butanamida inhibidor de la secretasa gamma

C19H27N3O4 425386-60-3

CH3 O H CH O 3 H H N CH3 H3C N N H HOH O

semuloparinum natricum semuloparin sodium sodium salt of a low molecular mass heparin that is obtained by phosphazene promoted depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy- 2-O-sulfo-α-L-threo-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-deoxy-6-O-sulfo-2-(sulfoamino)- D-glucopyranose structure at the reducing end of their chain; the molecular mass is defined by a repartition, no more than 40% is inferior to 1600 and no more than 11% is superior to 4500 Daltons, and by a mass-average value comprised between 2000 and 3000 Daltons; the degree of sulfatation is about 2.0 per disaccharidic unit anticoagulant

sémuloparine sodique sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation à l'aide de phosphazène d'héparine de muqueuse intestinale de porc. La majorité des composants présente une structure acide 4-déoxy-2-O-sulfo-α-L-thréo-hex- 4-énopyranosuronique à l'extrémité non réductrice et une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative du produit est définie par une répartition, au plus 40% inférieur à 1600 et au plus 11% supérieur à 4500, et une moyenne comprise entre 2000 et 3000 ; le degré de sulfatation est voisin de 2 par unité disaccharide anticoagulant

semuloparina sódica sal sódica de la heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización mediante un proceso controlado en el que se utiliza fosfazeno. La mayoría de los componentes presentan la estructura ácido 4-desoxi-2-O-sulfo-α-L-treo-hex-4-enopiranosurónico en el extremo no reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)- D-glucopiranosa en el extremo reductor de su cadena ; la masa molecular relativa del producto se define por una distribución, en la que, como máximo, un 40% es inferior a 1600 y, como máximo, un 11% es superior a 4500, y la media está comprendida entre 2000 y 3000 ; el grado de sulfatación es aproximadamente 2 por unidad de disacárido anticoagulante

9041-08-1

150 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

sivifenum sivifene 4,4'-{[2-(2,4-dinitrophenyl)hydrazinylidene]methylene}diphenol antiestrogen

sivifène 4,4'-{[(2,4-dinitrophényl)diazanylidène]méthylène}diphénol anti-oestrogène

sivifeno 4,4'-{[2-(2,4-dinitrofenil)hidrazinilideno]metileno}difenol antiestrógeno

C19H14N4O6 2675-35-6

HO O2N NO2

N N H

talarozolum talarozole N-{4-[(1R)-2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}- 1,3-benzothiazol-2-amine cytochrome P450 CYP26 inhibitor

talarozole N-{4-[(1R)-2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}benzothiazol- 2-amine inhibiteur du cytochrome P450 CYP26

talarozol N-{4-[(1R)-2-etil-1-(1H-1,2,4-triazol-1-il)butil]fenil}-1,3-benzotiazol- 2-amina inhibidor del citocromo P450 CYP26

C21H23N5S 870093-23-5

H H3C N N

H3C S

NH N N

talmapimodum talmapimod 2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophenyl)methyl]- 2,5-dimethylpiperazin-1-yl}carbonyl)-1-methyl-1H-indol-3-yl]- N,N-dimethyl-2-oxoacetamide immunomodulator

talmapimod 2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophényl)méthyl]- 2,5-diméthylpipérazin-1-yl}carbonyl)-1-méthyl-1H-indole-3-yl]- N,N-diméthyl-2-oxoacétamide immunomodulateur

talmapimod 2-[6-cloro-5-({(2R,5S)-4-[(4-fluorofenil)metil]-2,5-dimetilpiperazin- 1-il}carbonil)-1-metil-1H-indol-3-il]-N,N-dimetil-2-oxoacetamida inmunomodulador

151 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C27H30ClFN4O3 309913-83-5

H CH3 CH3 Cl N N N F O

H3CH O O N CH3 H3C

tanezumabum* tanezumab immunoglobulin G2, anti-[Homo sapiens nerve growth factor beta (NGFB)], humanized monoclonal antibody, RN624; gamma2 heavy chain (1-447) [humanized VH (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (108'-214')]; (223-223'':224-224'':227- 227'':230-230'')-tetradisulfide dimer analgesic

tanézumab immunoglobuline G2, anti-[Homo sapiens facteur de croissance beta des nerfs (NGFB)], anticorps monoclonal humanisé, RN624; chaîne lourde gamma2 (1-447) [VH humanisé (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')- disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (223- 223'':224-224'':227-227'':230-230'')-tetradisulfure analgésique

tanezumab inmunoglobulina G2, anti-[Homo sapiens factor beta de crecimiento de los nervios (NGFB)], anticuerpo monoclonal humanizado, RN624; cadena pesada gamma2 (1-447) [VH humanizada (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) - Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135- 214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (223-223'':224-224'':227-227'':230-230'')-tetradisulfuro analgésico

C6464H9942N1706O2026S46 880266-57-9

tasimelteonum tasimelteon N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}= propanamide melatonin receptor antagonist

tasimeltéon N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]méthyl}= propanamide antagoniste du récepteur de la mélatonine

tasimelteón N-{[(1R,2R)-2-(2,3-dihidro-1-benzofuran-4-il)ciclopropil]metil}= propanamida antagonista del receptor de melatonina

152 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

C15H19NO2 609799-22-6

CH3 N O H H H

tasisulamum tasisulam N-(5-bromothiophene-2-sulfonyl)-2,4-dichlorobenzamide antineoplastic

tasisulam N-[(5-bromothiophén-2-yl)sulfonyl]-2,4-dichlorobenzamide antinéoplasique

tasisulam N-(5-bromotiofeno-2-sulfonil)-2,4-diclorobenzamida antineoplásico

C11H6BrCl2NO3S2 519055-62-0

OO O Cl S S N Br H Cl

taspoglutidum taspoglutide [8-(2-amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide L-histidyl-2-methyl-L-alanyl-L-glutamylglycyl-L-threonyl- L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-valyl-L-seryl-L-seryl- L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl- L-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl- L-valyl-L-lysyl-2-methyl-L-alanyl-L-arginamide antidiabetic

taspoglutide [8-(acide 2-amino-2-méthylpropanoïque),35-(acide 2-amino- 2-méthylpropanoïque)]peptide 1 apparenté au glucagon humain (GLP-1)-(7-36)-peptidamide L-histidyl-2-méthyl-L-alanyl-L-glutamylglycyl-L-thréonyl- L-phénylalanyl-L-thréonyl-L-séryl-L-aspartyl-L-valyl-L-séryl-L-séryl- L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl- L-glutamyl-L-phénylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl- L-valyl-L-lysyl-2-méthyl-L-alanyl-L-arginamide antidiabétique

taspoglutida [8-(ácido 2-amino-2-metilpropanoico),35-(ácido 2-amino- 2-metilpropanoico)]péptido 1 relacionado con el glucagón humano- (7-36)-peptidamida L-histidil-2-metil-L-alanil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil- L-seril-L-aspartil-L-valil-L-seril-L-seril-L-tirosil-L-leucil-L-glutamilglicil- L-glutaminil-L-alanil-L-lisil-L-glutamil-L-fenilalanil-L-isoleucil-L-alanil- triptofil-L-leucil-L-valil-L-lisil-2-metil-L-alanil-L-arginamida hipoglucemiante

153 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C152H232N40O45 275371-94-3

HHis Aib Glu Gly Thr Phe Thr Ser Asp Val Ser Ser 710 Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala 20 30

Trp Leu Val Lys Aib Arg NH2

H3C CH3

Aib = N H O

tecovirimatum tecovirimat N-[1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro- 4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]- 4-(trifluoromethyl)benzamide antiviral

técovirimat N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro- 4,6-éthénocyclopropa[f]isoindol-2(1H)-yl)- 4-(trifluorométhyl)benzamide antiviral

tecovirimat N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahidro- 4,6-etenociclopropa[f]isoindol-2(1H)-il)- 4-(trifluorometil)benzamida antiviral

C19H15F3N2O3 816458-31-8

F3C O H N N O O

teneligliptinum teneligliptin {(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin- 1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone antidiabetic

ténéligliptine {(2S,4S)-4-[4-(3-méthyl-1-phényl-1H-pyrazol-5-yl)pipérazin- 1-yl]pyrrolidin-2-yl}(thiazolidin-3-yl)méthanone antidiabétique

teneligliptina {(2S,4S)-4-[4-(1-fenil-3-metil-1H-pirazol-5-il)piperazin-1-il]pirrolidin- 2-il}(1,3-tiazolidin-3-il)metanona hipoglucemiante

154 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

C22H30N6OS 760937-92-6

O H N N H N S H N H3C N N

tildipirosinum tildipirosin (4R,5S,6S,7R,9R,11E,13E,15R,16R-6-{[3,6-dideoxy- 3-(dimethylamino)-β-D-glucopyranosyl]oxy}-16-ethyl-4-hydroxy- 5,9,13-trimethyl-7-[2-(piperidin-1-yl)ethyl)-15-[(piperidin- 1-yl)methyl]oxacyclohexadeca-11,13-diene-2,10-dione antibiotic

tildipirosine (+)-(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[3,6-didéoxy- 3-(diméthylamino)-β-D-glucopyranosyl]oxy}-16-éthyl-4-hydroxy- 5,9,13-triméthyl-7-[2-(pipéridin-1-yl)éthyl]-15-(pipéridin- 1-ylméthyl)oxacyclohexadéca-11,13-diène-2,10-dione antibiotique

tildipirosina (+)-(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[3,6-didesoxi- 3-(dimetilamino)-β-D-glucopiranosil]oxi}-16-etil-4-hidroxi- 5,9,13-trimetil-7-[2-(piperidin-1-il)etil]-15-(piperidin- 1-ilmetil)oxaciclohexadeca-11,13-dieno-2,10-diona antibiótico

C41H71N3O8 328898-40-4

O H3C N H

CH3 CH3 H CH N O O 3 H3C CH3 H O H N H HO H HO O H OH H3C

tosedostatum tosedostat cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)- 2-oxoethyl]-4-methylpentanamido}-2-phenylacetate antineoplastic

tosédostat (2S)-2-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]- 4-méthylpentanoyl}amino)-2-phénylacétate de cyclopentyle antinéoplasique

tosedostat (2S)-2-{(2R)-2-[(1S)-1-hidroxi-2-(hidroxiamino)-2-oxoetil]- 4-metilpentanamido}-2-fenilacetato de ciclopentilo antineoplásico

155 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

C21H30N2O6 238750-77-1

H3C CH3 O H O H HO N N O H HOHO H

troplasminogenum alfa troplasminogen alfa thrombin-activable plasminogen: endo-[(558a(559)-558h(365))-human coagulation factor XI-(363- 370)-peptide]-des-(559-562)-[606(610)-lysine,623(627)-lysine]human plasminogen, glycoform α fibrinolytic and thrombolytic

troplasminogène alfa plasminogène activable par la thrombine : endo-[(558a(559)-558h(365))-facteur XI de coagulation humain- (363-370)-peptide]-dès-(559-562)-[606(610)-lysine,623(627)- lysine]plasminogène humain, glycoforme α fibrinolytique et thrombolytique

troplasminógeno alfa plasminógeno activable por la trombina : endo-[(558a(559)-558h(365))-facteur XI de coagulación humano- (363-370)-péptido]-des-(559-562)-[606(610)-lisina,623(627)-lisina] plasminógeno humano, glicoforma α fibrinolítico y trombolítico

C3875H5917N1107O1190S58 931101-84-7

EPLDDYVNTQ GASLFSVTKK QLGAGSIEEC AAKCEEDEEF TCRAFQYHSK 50 EQQCVIMAEN RKSSIIIRMR DVVLFEKKVY LSECKTGNGK NYRGTMSKTK 100 NGITCQKWSS TSPHRPRFSP ATHPSEGLEE NYCRNPDNDP QGPWCYTTDP 150 EKRYDYCDIL ECEEECMHCS GENYDGKISK TMSGLECQAW DSQSPHAHGY 200 IPSKFPNKNL KKNYCRNPDR ELRPWCFTTD PNKRWELCDI PRCTTPPPSS 250 GPTYQCLKGT GENYRGNVAV TVSGHTCQHW SAQTPHTHNR TPENFPCKNL 300 DENYCRNPDG KRAPWCHTTN SQVRWEYCKI PSCDSSPVST EQLAPTAPPE 350 LTPVVQDCYH GDGQSYRGTS STTTTGKKCQ SWSSMTPHRH QKTPENYPNA 400 GLTMNYCRNP DADKGPWCFT TDPSVRWEYC NLKKCSGTEA SVVAPPPVVL 450 LPDVETPSEE DCMFGNGKGY RGKRATTVTG TPCQDWAAQE PHRHSIFTPE 500 TNPRAGLEKN YCRNPDGDVG GPWCYTTNPR KLYDYCDVPQ CAAPSFDCGK 550 PQVEPKKCTT KIKPRIVGGC VAHPHSWPWQ VSLRTRFGMH FCGGTLISPE 600 WVLTAAHCLK KSPRPSSYKV ILGAHQKVNL EPHVQEIEVS RLFLEPTRKD 650 IALLKLSSPA VITDKVIPAC LPSPNYVVAD RTECFITGWG ETQGTFGAGL 700 LKEAQLPVIE NKVCNRYEFL NGRVQSTELC AGHLAGGTDS CQGDSGGPLV 750 CFEKDKYILQ GVTSWGLGCA RPNKPGVYVR VSRFVTWIEG VMRNN 795 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 30-54 34-42 84-162 105-145 133-157 166-243 169-297 187-226 215-238 256-333 277-316 305-328 358-435 379-418 407-430 462-541 483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Ser-249 Asn-289 Thr-346

156 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

ustekinumabum* ustekinumab immunoglobulin G1, anti-[Homo sapiens interleukin 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF p40)], Homo sapiens monoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) - IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16- IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231- 231")-bisdisulfide dimer immunomodulator

ustékinumab immunoglobulin G1, anti-[Homo sapiens interleukine 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF2 p40)], Homo sapiens anticorps monoclonal, CNTO 1275; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure immunomodulateur

ustekinumab inmunoglobulina G1, anti-[Homo sapiens interleukina 12B (IL12B, IL12 p40, factor 2 estimulante de las células natural killer NKSF2, factor 2 citotóxico de la maduraciòn de linfocitos, CLMF2, CMLF2 p40)], Homo sapiens anticuerpo monoclonal, CNTO 1275; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)- IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro inmunomodulador

C6482H10004N1712O2016S46 815610-63-0

vadimezanum vadimezan 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid antineoplastic (adjunctive agent)

vadimézan acide (5,6-diméthyl-9-oxo-9H-xanthén-4-yl)acétique antinéoplasique

vadimezán ácido 2-(5,6-dimetil-9-oxo-9H-xanten-4-ilo)ácetico antineoplásico (coadyuvante)

C17H14O4 117570-53-3

H3C O

CH3 CO2H

157 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

velneperitum velneperit (1r,4s)-4-(1,1-dimethylethanesulfonamido)- N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexanecarboxamide neuropeptide Y receptor antagonist

velnépérit (1r,4s)-4-(1,1-diméthyléthanesulfonamido)- N-[5-(trifluorométhyl)pyridin-2-yl]cyclohexanecarboxamide antagoniste du récepteur au neuropeptide Y

velneperit (1r,4s)-4-(1,1-dimetiletanosulfonamido)-N-[5-(trifluorometil)piridin- 2-il]ciclohexanocarboxamida antagonista del receptor del neuropéptido Y

C17H24F3N3O3S 342577-38-2

CF3 O OO H H3C S N N N H H H H3CCH3

158 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Non Proprietary Names (Prop. INN): List 95 Dénominations communes internationales proposées (DCI Prop.): Liste 95 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 95 (WHO Drug Information, Vol. 20, No. 2, 2006) p. 140 delete/supprimer/suprimáse insert/insérer/insértese piraxostatum niraxostatum piraxostat niraxostat piraxostat niraxostat piraxostat niraxostat

Proposed International Non Proprietary Names (Prop. INN): List 97 Dénominations communes internationales proposées (DCI Prop.): Liste 97 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 97 (WHO Drug Information, Vol. 21, No. 2, 2007) p. 135 suprimáse insertése albinterferón alfa 2b albinterferón alfa-2b p. 141 supprimer insérer céftaroline fosamil ceftaroline fosamil p. 166 delete/supprimer/suprimáse insert/insérer/insértese tiliquinatinum intiquinatinum tiliquinatine intiquinatine tiliquinatine intiquinatine tiliquinatina intiquinatina

Proposed International Non Proprietary Names (Prop. INN): List 98 Dénominations communes internationales proposées (DCI Prop.): Liste 98 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 98 (WHO Drug Information, Vol. 21, No. 4, 2007) p. 324 baminerceptum baminercept replace the chemical structure by the following baminercept remplacer la structure chimique par la suivante baminercept sustitúyase la fórmula desarrollada por la siguiente

159 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

Monomer / Monomère / Monómero AVPPYASENQ TCRDQEKEYY EPQHRICCSR CPPGTYVSAK CSRIRDTVCA 50 TCAENSYNEH WNYLTICQLC RPCDPVMGLE EIAPCTSKRK TQCRCQPGMF 100 CAAWALECTH CELLSDCPPG TEAELKDEVG KGNNHCVPCK AGHFQNTSSP 150 SARCQPHTRC ENQGLVEAAP GTAQSDTTCK NPLEPLPPEM SGTMVDKTHT 200 CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF 250 NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN 300 KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS 350 DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC 400 SVMHEALHNH YTQKSLSLSP G 421

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 12-27 12'-27' 28-41 28'-41' 31-49 31'-49' 52-67 52'-67' 70-85 70'-85' 73-93 73'-93' 95-101 95'-101' 108-117 108'-117' 111-136 111'-136' 139-154 139'-154' 201-201' 204-204' 236-296 236'-296' 342-400 342'-400'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-9 Asn-9' Asn-146 Asn-146' Asn-272 Asn-272' p. 325 suprimáse insertése besifloxacina besifloxacino p. 334 flopristinum remplacer la propriété par la suivante flopristine antibactérien p. 343 otelixizumabum otelixizumab sustitúyase el nombre químico por el siguiente inmunoglobulina G1, anti-(CD3E humano) anticuerpo monoclonal humanizado/quimérico TRX4 (ChAglyCD3); cadena pesada gamma1 humanizada 299N>A [VH humanizada (Homo sapiens FR/Rattus sp. CDR) (119 residuos [8.8.12])- Homo sapiens IGHG1*01, 180N>A (CH2 84.4) (222-216’)- disulfuro con la cadena lambda quimérica 111G>R [Rattus sp. V-LAMBDA (110 residuos [8.3.9])-Homo sapiens IGLC2*01, 1G>R (1.5)] ; dímero (228-228”: 231- 231”)-bisdisulfuro p. 344 preladenantum préladénant remplacer le nom chimique par le suivant 2-(furan-2-yl)-7-(2-{4-[4-(2-méthoxyéthoxy)phényl]pipérazin-1-yl}éthyl)-7H- pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine p. 346 tenatumomabum tenatumomab replace the chemical structure by the following ténatumomab remplacer la structure chimique par la suivante tenatumomab sustitúyase la fórmula desarrollada por la siguente

160 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

Heavy chain / Chaîne lourde / Cadena pesada EIQLQQSGPE LVKPGASVKV SCKASGYAFT SYNMYWVKQS HGKSLEWIGY 50 IDPYNGVTSY NQKFKGKATL TVDKSSSTAY MHLNSLTSED SAVYYCARGG 100 GSIYYAMDYW GQGTSVTVSS AKTTPPSVYP LAPGCGDTTG SSVTLGCLVK 150 GYFPESVTVT WNSGSLSSSV HTFPALLQSG LYTMSSSVTV PSSTWPSQTV 200 TCSVAHPASS TTVDKKLEPS GPISTINPCP PCKECHKCPA PNLEGGPSVF 250 IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVQISWFVNN VEVHTAQTQT 300 HREDYNSTIR VVSTLPIQHQ DWMSGKEFKC KVNNKDLPSP IERTISKIKG 350 LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG FNPGDISVEW TSNGHTEENY 400 KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD SFSCNVRHEG LKNYYLKKTI 450 SRSPGK 456

Light chain/ Chaîne légère / Cadena ligera DIVMTQAAPS VPVTPGESVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ 50 LLIYRMSNLA SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCMQHLEYP 100 LTFGAGTKLE LKRADAAPTV SIFPPSSEQL TSGGASVVCF LNNFYPKDIN 150 VKWKIDGSER QNGVLNSWTD QDSKDSTYSM SSTLTLTKDE YERHNSYTCE 200 ATHKTSTSPI VKSFNRNEC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Bold and underlined Cysteins are those involved in disulphide bridges.

* Electronic structure available on Mednet: http://mednet.who.int/ * Structure électronique disponible sur Mednet: http://mednet.who.int/ * Estructura electrónica disponible en Mednet: http://mednet.who.int/

161 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

ANNEX 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

The following procedure shall be followed by the World Health Organization (hereinafter also referred to as “WHO”) in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11 of the World Health Assembly, and in the substitution of such names.

Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted.

Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members hereinafter referred to as “the INN Expert Group”, for consideration in accordance with the “General principles for guidance in devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this procedure2. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed international nonproprietary name is being considered. a) Such notice shall be given by publication in WHO Drug Information3 and by letter to Member States and to national and regional pharmacopoeia commissions or other bodies designated by Member States.

i) Notice shall also be sent to the person who submitted the proposal (“the original applicant”) and other persons known to be concerned with a name under consideration. b) Such notice shall:

i) set forth the name under consideration;

ii) identify the person who submitted the proposal for naming the substance, if so requested by such person;

iii) identify the substance for which a name is being considered;

iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

v) state the authority under which WHO is acting and refer to these rules of procedure. c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO.

Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of publication, under article 3, of the name in WHO Drug Information.

1 See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution EB15.R7 and amended in resolutions EB43.R9 and EB115.R4.

2 See Annex 2.

3 Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.

162 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in WHO Drug Information.

Such objection shall:

i) identify the person objecting;

ii) state his or her interest in the name;

iii) set forth the reasons for his or her objection to the name proposed.

Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Secretariat shall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a recommended international nonproprietary name.

Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat shall: a) request that it be recognized as the nonproprietary name for the substance; and b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name and to prohibit registration of the name as a trademark or trade name.

Article 9 a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved through other interventions than a possible substitution of a previously recommended international nonproprietary name, or in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested person. Such proposals shall be submitted on the form provided therefore and shall:

i) identify the person making the proposal;

ii) state his or her interest in the proposed substitution; and

iii) set forth the reasons for the proposal; and

iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to resolve the situation, and the reasons why these other interventions were inadequate.

Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with the General principles, which takes into account the pharmaceutical substance for which the new substitute international nonproprietary name is being proposed.

The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations).

In addition, the Secretariat shall request comments on the proposal from:

i) Member States and national and regional pharmacopoeia commissions or other bodies designated by Member States (by including a notice to that effect in the letter referred to in article 3(a), and

ii) any other persons known to be concerned by the proposed substitution.

163 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

The request for comments shall:

i) state the recommended international nonproprietary name that is being proposed for substitution (and the proposed substitute name, if provided);

ii) identify the person who submitted the proposal for substitution (if so requested by such person);

iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution;

iv) set forth the time within which comments will be received and the person and place to whom they should be directed; and

v) state the authority under which WHO is acting and refer to these rules of procedure.

Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the request for comments. b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert Group for further processing. Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed for substitution.

In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3 and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously recommended international nonproprietary name and that Member States may wish to make transitional arrangements in order to accommodate existing products that use the previously recommended international nonproprietary name on their label in accordance with national legislation.

If, after consideration of the proposal for substitution and the comments received in accordance with the procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why the proposal for substitution was not considered sufficiently compelling).

Article 10 - A working process, intended to serve as a guide for the INN Expert Group in the implementation of this procedure, is attached hereto as an appendix.

164 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

ANNEX 2

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

These primary principles are to be implemented by using the following secondary principles:

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and “ibufenac sodium”.

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base. For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t” instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and “k” should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.2 Where a stem is shown without any hyphens it may be used anywhere in the name.

Latin English

-acum -ac anti-inflammatory agents, ibufenac derivatives -adolum -adol } analgesics -adol- -adol-} -astum -ast antiasthmatic, antiallergic substances not acting primarily as antihistaminics -astinum -astine antihistaminics -azepamum -azepam diazepam derivatives bol bol steroids, anabolic -cain- -cain- class I antiarrhythmics, procainamide and lidocaine derivatives -cainum -caine local anaesthetics

1 In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are fully discussed. The guiding principles were updated during the 13th consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983).

2 A more extensive listing of stems is contained in the working document WHO/PSM/QSM/2006.3 which is regularly updated and can be requested from the INN Programme, WHO, Geneva.

165 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

cef- cef- antibiotics, cefalosporanic acid derivatives -cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives -conazolum -conazole systemic antifungal agents, miconazole derivatives cort cort corticosteroids, except prednisolone derivatives -coxibum -coxib selective cyclo-oxygenase inhibitors -entanum -entan endothelin receptor antagonists gab gab gabamimetic agents gado- gado- diagnostic agents, gadolinium derivatives -gatranum -gatran thrombin inhibitors, antithrombotic agents gest gest steroids, progestogens gli gli antihyperglycaemics io- io- iodine-containing contrast media -metacinum -metacin anti-inflammatory, indometacin derivatives -mycinum -mycin antibiotics, produced by Streptomyces strains -nidazolum -nidazole antiprotozoal substances, metronidazole derivatives -ololum -olol β-adrenoreceptor antagonists -oxacinum -oxacin antibacterial agents, nalidixic acid derivatives -platinum -platin antineoplastic agents, platinum derivatives -poetinum -poetin erythropoietin type blood factors -pril(at)um -pril(at) angiotensin-converting enzyme inhibitors -profenum -profen anti-inflammatory substances, ibuprofen derivatives prost prost prostaglandins -relinum -relin pituitary hormone release-stimulating peptides -sartanum -sartan angiotensin II receptor antagonists, antihypertensive (non-peptidic) -vaptanum -vaptan vasopressin receptor antagonists vin- vin- } vinca-type alkaloids -vin- -vin-}

ANNEXE 1

PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES PHARMACEUTIQUES1

L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS ») observe la procédure exposée ci- dessous pour l’attribution de dénominations communes internationales recommandées pour les substances pharmaceutiques, conformément à la résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles dénominations.

Article 1 - Les propositions de dénominations communes internationales recommandées et les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe administrative destinée uniquement à couvrir les coûts correspondants assumés par le Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le Secrétariat et peut être modifié de temps à autre.

Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour la formation de dénominations communes internationales pour les substances pharmaceutiques » reproduites ci-après2. La dénomination acceptée est la dénomination employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de cette règle.

1 Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4.

2 Voir annexe 2.

166 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de dénomination commune internationale est à l’étude. a) Cette notification est faite par une insertion dans WHO Drug Information1 et par l’envoi d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée ou autres organismes désignés par les Etats Membres.

i) Notification est également faite à la personne qui a soumis la proposition (« le demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un intérêt notoire. b) Cette notification contient les indications suivantes :

i) dénomination mise à l’étude;

ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la substance, si cette personne le demande ;

iii) définition de la substance dont la dénomination est mise à l’étude ;

iv) délai pendant lequel seront reçues les observations et les objections à l’égard de cette dénomination ; nom et adresse de la personne habilitée à recevoir ces observations et objections ;

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par l’OMS.

Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par toute personne, dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3).

Article 5 - Toute personne intéressée peut formuler une objection formelle contre la dénomination proposée dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3).

Cette objection doit s’accompagner des indications suivantes :

i) nom de l’auteur de l’objection ;

ii) intérêt qu’il ou elle porte à la dénomination en cause ;

iii) raisons motivant l’objection contre la dénomination proposée.

Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination commune internationale recommandée tant qu’une objection formelle présentée conformément à l’article 5 n’est pas levée.

Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les objections présentées ont été levées, le Secrétariat fait une notification conformément aux dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie par l’OMS en tant que dénomination commune internationale recommandée.

Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une dénomination commune internationale recommandée, le Secrétariat : a) demande que cette dénomination soit reconnue comme dénomination commune de la substance considérée ; et b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette dénomination comme marque ou appellation commerciale.

1 Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la Santé.

167 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

Article 9 - a) Dans le cas exceptionnel où une dénomination commune internationale déjà recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou en comporte un risque démontrable, en raison d’une similitude avec une autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres interventions que le remplacement éventuel d’une dénomination commune internationale déjà recommandée, ou dans le cas où une dénomination commune internationale déjà recommandée diffère sensiblement de la dénomination commune approuvée dans un nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui justifient le remplacement d’une dénomination commune internationale recommandée, toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes :

i) nom de l’auteur de la proposition ;

ii) intérêt qu’il ou elle porte au remplacement proposé ;

iii) raisons motivant la proposition ; et

iv) description, faits à l’appui, des autres interventions entreprises pour tenter de régler le problème et exposé des raisons pour lesquelles ces interventions ont échoué.

Les propositions peuvent comprendre une proposition de nouvelle dénomination commune internationale de remplacement, établie conformément aux Directives générales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune internationale de remplacement est proposée.

Le Secrétariat transmet une copie de la proposition pour examen, conformément à la procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles).

De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des observations sur la proposition :

i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet dans la lettre mentionnée à l’article 3.a), et

ii) toutes autres personnes portant au remplacement proposé un intérêt notoire.

La demande d’observations contient les indications suivantes :

i) dénomination commune internationale recommandée pour laquelle un remplacement est proposé (et la dénomination de remplacement proposée, si elle est fournie) ;

ii) nom de l’auteur de la proposition de remplacement (si cette personne le demande) ;

iii) définition de la substance faisant l’objet du remplacement proposé et raisons avancées pour le remplacement ;

iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la personne habilitée à recevoir ces commentaires ; et

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement.

Des observations sur la proposition de remplacement peuvent être communiquées par toute personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations. b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts des DCI pour qu’il y donne suite.

Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer.

168 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des DCI pour qu’il y donne suite, le Groupe choisit une nouvelle dénomination commune internationale conformément aux Directives générales mentionnées à l’article 2 et selon la procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son successeur (si ce n’est pas la même personne que celle qui a proposé le remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui utilisent la dénomination commune internationale déjà recommandée sur leur étiquette conformément à la législation nationale.

Si, après examen de la proposition de remplacement et des observations communiquées conformément à la procédure exposée plus haut, le Groupe d’experts des DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination commune internationale déjà recommandée, cette dernière est conservée (étant entendu toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement, ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions nationales et régionales de pharmacopée, les autres organismes désignés par les Etats Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination commune internationale déjà recommandée (avec une brève description de la ou des raisons pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative).

Article 10 - Une méthode de travail, destinée à servir de guide pour le Groupe d’experts des DCI en vue de la mise en œuvre de cette procédure, est jointe en appendice au présent texte.

ANNEXE 2

DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES1

1. Les dénominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur excessive, ni prêter à confusion avec des appellations déjà couramment employées.

2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les dénominations susceptibles d’évoquer pour les malades des considérations anatomiques, physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du possible.

Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants :

ٛ .Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique, on tiendra compte de la possibilité de former ultérieurement d’autres DCI appropriées pour les substances apparentées du même groupe.

1 Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes (segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies. Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques (Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983).

169 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple «oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique».

5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive). En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé.

6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au trait d’union.

7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ; l’usage des lettres « h » et « k » sera aussi évité.

8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les dénominations déjà officiellement adoptées par un pays.

9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des exemples de segments-clés pour des groupes de substances, surtout pour des groupes récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination.

Latin Français

-acum -ac substances anti-inflammatoires du groupe de l’ibufénac -adolum -adol } analgésiques -adol- -adol- } -astum -ast antiasthmatiques, antiallergiques n’agissant pas principalement en tant qu’antihistaminiques -astinum -astine antihistaminiques -azepamum -azépam substances du groupe du diazépam bol bol stéroïdes anabolisants -cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et de la lidocaïne -cainum -caïne anesthésiques locaux cef- céf- antibiotiques, dérivés de l’acide céphalosporanique -cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique -conazolum -conazole agents antifongiques systémiques du groupe du miconazole cort cort corticostéroïdes, autres que les dérivés de la prednisolone -coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase -entanum -entan antagonistes du récepteur de l’endothéline gab gab gabamimétiques gado- gado- agents diagnostiques, dérivés du gadolinium -gatranum -gatran antithrombines, antithrombotiques gest gest stéroïdes progestogènes gli gli antihyperglycémiants io- io- produits de contraste iodés -metacinum -métacine substances anti-inflammatoires du groupe de l’indométacine -mycinum -mycine antibiotiques produits par des souches de Streptomyces -nidazolum -nidazole substances antiprotozoaires du groupe du métronidazole -ololum -olol antagonistes des récepteurs β-adrénergiques -oxacinum -oxacine substances antibactériennes du groupe de l’acide nalidixique -platinum -platine antinéoplasiques, dérivés du platine -poetinum -poétine facteurs sanguins de type érythropoïétine -pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine -profenum -profène substances anti-inflammatoires du groupe de l’ibuprofène prost prost prostaglandines

1 Une liste plus complète de segments-clés est contenue dans le document de travail WHO/PSM/QSM/2006.3 qui est régulièrement mis à jour et qui peut être demandé auprès du programme des DCI, OMS, Genève.

170 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

-relinum -réline peptides stimulant la libération d’hormones hypophysaires -sartanum -sartan antagonistes d’un récepteur de l’angiotensine II, antihypertenseurs (non peptidiques) -vaptanum -vaptan antagonistes du récepteur de la vasopressine vin- vin- } alcaloïdes du type vinca -vin- -vin- }

ANEXO 1

PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1

La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a continuación tanto para seleccionar denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11, como para sustituir esas denominaciones.

Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla periódicamente.

Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su estudio, en adelante designados como «el Grupo de Expertos en DCI», para que las examinen de conformidad con los «Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas», anexos a este procedimiento.2 A menos que haya poderosas razones en contra, la denominación aceptada será la empleada por la persona que haya descubierto o fabricado y comercializado por primera vez esa sustancia farmacéutica.

Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en estudio un proyecto de denominación internacional. a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3 y el envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros.

i) La notificación será enviada también a la persona que haya presentado la propuesta («el solicitante inicial») y a otras personas que tengan un interés especial en una denominación objeto de estudio. b) En esa notificación se incluirán los siguientes datos:

i) la denominación sometida a estudio;

ii) la identidad de la persona que ha presentado la propuesta de denominación de la sustancia, si lo pide esa persona;

iii) la identidad de la sustancia cuya denominación está en estudio;

iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y

v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

1 Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4..

2 Véase el anexo 2.

3 Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud.

171 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación propuesta, durante el periodo en que la OMS la tenga en estudio.

Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3.

Artículo 5 - Toda persona interesada puede presentar una objeción formal a una denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Esa objeción deberá acompañarse de los siguientes datos:

i) la identidad de la persona que formula la objeción;

ii) las causas que motivan su interés por la denominación; y

iii) las causas que motivan su objeción a la denominación propuesta.

Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo 5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objeción. La OMS no seleccionará como denominación común internacional una denominación a la que se haya hecho una objeción formal, presentada según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organización examine otra denominación o denominaciones sustitutivas.

Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo 5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará, conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido seleccionada por la OMS como denominación común internacional recomendada.

Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional, conforme a lo previsto en el artículo 7, la Secretaría: a) solicitará que esta denominación sea reconocida como denominación común para la sustancia de que se trate; y b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada como marca de fábrica o como nombre comercial.

Artículo 9 a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en las prácticas farmacéuticas y/o de prescripción, una denominación común internacional recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución de esa denominación común internacional recomendada anteriormente; en el caso de que una denominación común internacional recomendada anteriormente difiera considerablemente de la denominación común aprobada en un número importante de Estados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominación común internacional recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que se proporcionen a estos efectos e incluirán los siguientes datos:

i) la identidad de la persona que presenta la propuesta;

ii) las causas que motivan su interés en la sustitución propuesta;

iii) las causas que motivan la propuesta; y

iv) una descripción, acompañada de pruebas documentales, de las otras medidas que se hayan adoptado con el fin de resolver la situación y de los motivos por los cuales dichas medidas no han sido suficientes.

Entre esas propuestas podrá figurar una relativa a una nueva denominación común internacional sustitutiva, formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común internacional sustitutiva.

La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el párrafo b) infra.

172 WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99

Además, la Secretaría solicitará observaciones sobre la propuesta:

i) a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros (ello se hará incluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del artículo 3), y

ii) a cualquier persona que tenga un interés especial en la sustitución propuesta.

Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos:

i) la denominación común internacional recomendada que se propone sustituir (y la denominación sustitutiva propuesta, si se ha facilitado);

ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo pide esa persona);

iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las razones para presentar la propuesta de sustitución;

iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y

v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones. b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de Expertos en DCI para que la tramite. No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone.

En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI para que la tramite, este grupo seleccionará una nueva denominación común internacional de conformidad con los Principios generales a los que se refiere el artículo 2 y al procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), se indicará que la nueva denominación sustituye a una denominación común internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional recomendada anteriormente que se haya sustituido.

En caso de que, después de haber estudiado la propuesta de sustitución y los comentarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas para sustituir una denominación común internacional recomendada anteriormente, esta denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones nacionales y regionales de las farmacopeas o a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga interés en la sustitución propuesta, que, pese a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación común internacional recomendada anteriormente (con una descripción de la o las razones por las que se ha considerado que la propuesta de sustitución no estaba respaldada por razones suficientemente poderosas).

Artículo 10 - A fin de proporcionar orientación al Grupo de Expertos en DCI para la aplicación del presente procedimiento, se incluye como apéndice un texto relativo al método de trabajo.

173 Proposed INN: List 99 WHO Drug Information, Vol. 22, No. 2, 2008

ANEXO 2

PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES 1 COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS

1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con denominaciones de uso común.

2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o terapéuticas para el paciente.

Estos principios primarios se pondrán en práctica utilizando los siguientes principios secundarios:

3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo.

4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica», «ibufenaco» y «ibufenaco sódico».

5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos. En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse adecuadamente por separado, como componentes independientes de una sustancia cuaternaria y no como sales de una amina.

6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo de guiones.

7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá evitar el empleo de las letras «h» y «k».

8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios, recibirán una consideración preferente las denominaciones propuestas por la persona que haya descubierto las sustancias, o que fabrique y comercialice por primera vez una sustancia farmacéutica, así como las denominaciones ya adoptadas oficialmente en cualquier país.

9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen muchas otras partículas que se usan habitualmente.2 Cuando una partícula aparece sin guión alguno, puede utilizarse en cualquier lugar de la palabra.

1 En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este cambio. Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983).

2 En el documento de trabajo WHO/PSM/QSM/2006.3, que se actualiza periódicamente y puede solicitarse al Programa sobre Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas.

174